ClinicalTrials.gg
CompletedNCT02670915onset®7Updated Jun 5, 2019Results posted

Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Children and Adolescents With Type 1 Diabetes

A Phase 3 interventional study of Faster-acting insulin aspart and insulin aspart in Diabetes and Diabetes Mellitus, Type 1, sponsored by Novo Nordisk A/S. Completed at 155 sites in 18 countries. Open to participants aged 1 Year to 17 Years. Per ClinicalTrials.gov, last updated 2019-06-05.

Primary conditionDiabetes Mellitus, Type 1Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 1
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 1, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
834
Allocation
Randomized
Ages
1 Year to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 87 studies testing Insulin Aspart in Diabetes Mellitus, Type 1 — 2 open to participants now, 2 under way, none of them phase 3. Insulin Aspart · Diabetes Mellitus, Type 1.

Enrollment
2nd of 87
834 · median 50
Started
2016
with 4 others
Phase 3
24 of 87
none open now
Registered
61st of 87
by date
Lead sponsor
55 of 87
Novo Nordisk A/S

Among the 87 studies testing Insulin Aspart in Diabetes Mellitus, Type 1, this one is the 2nd largest by enrollment, is one of 5 that started in 2016, is one of 24 in phase 3, and was the 61st registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

2 of the 87 studies testing Insulin Aspart in Diabetes Mellitus, Type 1 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About Insulin Aspart

Insulin Aspart: first FDA approval 2000 (NOVOLOG PENFILL), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 412 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 258 (63%) stop at 75 or younger; 185 take children under 18; 64 take healthy volunteers.

This study: 1 Year to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 87 studies testing Insulin Aspart in Diabetes Mellitus, Type 1, or all of them as a file.
02

Study summary

This trial is conducted globally. The aim of the trial is to investigate efficacy and safety of faster-acting insulin aspart compared to NovoRapid® both in combination with insulin degludec in children and adolescents with type 1 diabetes.

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 1

Browse trials for

04

In context

Diabetes Mellitus, Type 1 Reclassified

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

This study's enrollment of 834 is above the median of 40 across 2,820 interventional studies indexed under Diabetes Mellitus, Type 1.

Browse Diabetes Mellitus, Type 1 studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Diabetes Mellitus, Type 1, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
1 Year to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: - Male or female, 1 year above or equal to age below 18 years at the time of signing and below 18 years at the time of randomisation - Diagnosed with type 1 diabetes mellitus (based on clinical judgement and supported by laboratory analysis as per local guidelines) - Ongoing daily treatment with a basal-bolus insulin regimen using basal insulin analogue or Neutral Protamine Hagedorn (NPH) insulin for at least 90 days prior to the screening visit - (glycosylated ) below or equal 9.5% (80 mmol/mol) analysed by the central laboratory at the screening visit Exclusion Criteria: - More than one episode of diabetic ketoacidosis requiring hospitalisation within the last 90 days prior to the screening visit - Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria in a period of 90 days before screening

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
834 participants (actual)

Study arms

  • Experimental
    Meal-time faster-acting insulin aspart and insulin degludec

    Drug: Faster-acting insulin aspart · Drug: insulin degludec

  • Active comparator
    Meal-time NovoRapid® (insulin aspart) and insulin degludec

    Drug: insulin aspart · Drug: insulin degludec

  • Experimental
    Post-meal faster-acting insulin aspart and insulin degludec

    Drug: Faster-acting insulin aspart · Drug: insulin degludec

Interventions

07

What researchers measure

Primary outcomes

  1. Change in the Percentage of HbA1c

    Change from baseline (week 0) in glycosylated haemoglobin (HbA1c) was evaluated after 26 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In-trial period: the observation period from date of randomisation until last trial-related participant-site contact and included data collected after a subject discontinued trial product.

    Time frame: Week 0, Week 26

Secondary outcomes

  1. Change in 8-point SMPG Profile: Mean PPG Over All Three Meals

    Change from baseline (week 0) in mean post prandial glucose (PPG) over all three meals was evaluated after 26 weeks of randomisation. PPG for each meal (breakfast, lunch and main evening meal) was recorded by the participant as part of the 8-point self-measured plasma glucose (SMPG) profile. Mean PPG over all three meals was derived as the mean of all corresponding mean meal. The results are based on the last in-trial value.

    Time frame: Week 0, Week 26

  2. Change in 8-point SMPG Profile: PPG Increment Over All Three Meals

    Change from baseline (week 0) in mean PPG increment over all three meals was evaluated after 26 weeks of randomisation. Postprandial glucose (PPG) increment for each meal (breakfast, lunch and main evening meal) was derived from the 8-point profile as the difference between PPG (1 hour after the meal) values and the plasma glucose (PG) value before meal. The mean of the derived increments was then calculated separately for each meal. Mean PPG increment over all three meals was derived as the mean of all corresponding mean meal increments. The results are based on the last in-trial value.

    Time frame: Week 0, Week 26

  3. Change in 8-point SMPG Profile: Individual Meal (Breakfast, Lunch and Main Evening Meal) PPG

    Change from baseline (week 0) in individual meal (breakfast, lunch and main evening meal) PPG was evaluated after 26 weeks of randomisation. PPG for each meal was recorded by the participant as part of the 8-point SMPG profile. The results are based on the last in-trial value.

    Time frame: Week 0, Week 26

  4. Change in 8-point SMPG Profile: Individual Meal (Breakfast, Lunch and Main Evening Meal) PPG Increment

    Change from baseline (week 0) in individual meal (breakfast, lunch and main evening meal) PPG increment was evaluated after 26 weeks of randomisation. PPG increment for each meal was derived from the 8-point profile as the difference between PPG values (1 hour after the meal) and the PG value before meal. The results are based on the last in-trial value.

    Time frame: Week 0, Week 26

  5. Change in 8-point SMPG Profile: Mean of the 8-point Profile

    Change from baseline (week 0) in mean of the 8-point SMPG profile was evaluated after 26 weeks of randomisation. SMPG values were recorded at 8 time-points on two consecutive days: before and after (60 minute after the start of the meal) breakfast, lunch and main evening meal, before bedtime, and before breakfast on the next day. Mean of the 8-point profile was derived as the mean of all corresponding mean SMPG recorded at 8 different time points. The results are based on the last in-trial value.

    Time frame: Week 0, Week 26

  6. Fluctuation in the 8-point SMPG Profile

    Fluctuation in the 8-point SMPG profile was evaluated after 26 weeks of randomisation. Fluctuation in 8-point SMPG profile was the average absolute difference from the mean of the SMPG profile. The results are based on the last in-trial value.

    Time frame: Week 26

  7. Change in FPG

    Change from baseline (week 0) in fasting plasma glucose (FPG) was evaluated after 26 weeks of randomisation. The results are based on the last in-trial value.

    Time frame: Week 0, Week 26

  8. Change in 1,5-anhydroglucitol

    Change from baseline (week 0) in 1,5-anhydroglucitol was evaluated after 26 weeks of randomisation. The results are based on the last in-trial value.

    Time frame: Week 0, Week 26

  9. Percentage of Subjects Reaching HbA1c Target (HbA1c Less Than 7.5 %) According to ISPAD Guidelines

    Percentage of participants (yes/no) reaching HbA1c less than 7.5 % according to International Society for Pediatric and Adolescent Diabetes (ISPAD) guidelines was evaluated after 26 weeks of randomisation. The results are based on the last in-trial value.

    Time frame: Week 26

  10. Percentage of Subjects Reaching HbA1c Target (HbA1c Less Than 7.5 %) According to ISPAD Guidelines, Without Severe Hypoglycaemia

    Percentage of participants (yes/no) reaching HbA1c less than 7.5 % according to ISPAD guidelines, without severe hypoglycaemia was evaluated after 26 weeks of randomisation. Severe hypoglycaemia according to ISPAD guidelines: hypoglycaemic episode associated with severe neuroglycopenia, usually resulting in coma or seizure and requiring parenteral therapy (glucagon or intravenous glucose). The results are based on the last in-trial value.

    Time frame: Week 26

  11. Insulin Dose (Units/Day): Total Basal

    Total basal insulin dose (Units/day) was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period: the observation period from date of first dose of randomised NovoRapid®/NovoLog® / faster aspart and no later than 7 days after the day of last dose of NovoRapid®/NovoLog® / faster aspart. The on-treatment observation period includes data collected up to and including 7 days after treatment discontinuation. Number of participants analysed = number of participants contributed to the analysis. Analysis population description: Safety analysis set (SAS) included all participants receiving at least one dose of the investigational product (faster aspart) or its comparator (NovoRapid®/NovoLog®).

    Time frame: Week 26

  12. Insulin Dose (Units/Day): Total Bolus

    Total bolus insulin dose (Units/day) was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.

    Time frame: Week 26

  13. Insulin Dose (Units/Day): Individual Meal Insulin Dose

    Individual meal (breakfast, lunch and main evening meal) insulin dose (Units/day) was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value.

    Time frame: Week 26

  14. Insulin Dose (Units/kg/Day): Total Basal

    Total basal insulin dose (Units/kg/day) was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.

    Time frame: Week 26

  15. Insulin Dose (Units/kg/Day): Total Bolus

    Total bolus insulin dose (Units/kg/day) was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.

    Time frame: Week 26

  16. Insulin Dose (Units/kg/Day): Individual Meal Insulin Dose

    Individual meal (breakfast, lunch and main evening meal) insulin dose (Units/kg/day) was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.

    Time frame: Week 26

  17. Change of Time Spent in Low Interstitial Glucose (IG) (IG <=3.9 mmol/L [70 mg/dL])

    Change from baseline (week 0) in the time spent in low IG (\<=3.9 mmol/L \[70 mg/dL\]) based on continuous glucose monitoring (CGM) was evaluated after 26 weeks of randomisation. A subgroup of participants wore a CGM for between 11 and 13 days up to week 0 (randomisation) and up to week 26 to monitor their IG on a continuous basis. The results are based on the last in-trial value.

    Time frame: Week 0, Week 26

  18. Incidence of Episodes With IG <=2.5, 3.0, 3.9 mmol/L (45, 54, 70 mg/dL) and IG >10.0, 12.0 mmol/L (180, 216 mg/dL)

    Incidence of episodes (number of episodes per 24 hours) with IG \<=2.5, 3.0, 3.9 mmol/L (45, 54, 70 mg/dL) and IG \>10.0, 12.0 mmol/L (180, 216 mg/dL) based on CGM was calculated after 26 weeks of randomisation. A subgroup of participants wore a CGM for between 11 and 13 days up to week 0 (randomisation) and up to week 26 to monitor their IG on a continuous basis. The results are based on the last in-trial value.

    Time frame: Week 26

  19. Percentage of Time Spent With IG <=2.5, 3.0, 3.9 mmol/L (45, 54, 70 mg/dL) and IG >10.0, 12.0 mmol/L (180, 216 mg/dL)

    Percentage of time spent with IG \<=2.5, 3.0, 3.9 mmol/L (45, 54, 70 mg/dL) and IG \>10.0, 12.0 mmol/L (180, 216 mg/dL) based on CGM was evaluated after 26 weeks of randomisation. A subgroup of participants wore a CGM for between 11 and 13 days up to week 0 (randomisation) and up to week 26 to monitor their IG on a continuous basis. The results are based on the last in-trial value.

    Time frame: Week 26

  20. Percentage of Time Spent Within IG Target 4.0-10.0 mmol/L (71-180 mg/dL) Both Included

    Percentage of time spent within IG target 4.0-10.0 mmol/L (71-180 mg/dL), both included based on CGM was evaluated after 26 weeks of randomisation. A subgroup of participants wore a CGM for between 11 and 13 days up to week 0 (randomisation) and up to week 26 to monitor their IG on a continuous basis. The results are based on the last in-trial value.

    Time frame: Week 26

  21. Change in Mean IG Increment (0-1 Hours and 0-2 Hours After Start of the Meal)

    Change from baseline (week 0) in mean IG increment (0-1 hours and 0-2 hours after start of the meal) based on CGM was evaluated after 26 weeks of randomisation. A subgroup of participants wore a CGM for between 11 and 13 days up to week 0 (randomisation) and up to week 26 to monitor their IG on a continuous basis. Presented values are mean of all the meals (breakfast, lunch and evening meal). The results are based on the last in-trial value.

    Time frame: Week 0, Week 26

  22. Change in Mean IG Peak After Start of Meal

    Change from baseline (week 0) in mean IG peak after start of meal based on CGM was evaluated after 26 weeks of randomisation. A subgroup of participants wore a CGM for between 11 and 13 days up to week 0 (randomisation) and up to week 26 to monitor their IG on a continuous basis. Presented values are mean of all the meals (breakfast, lunch and evening meal). The results are based on the last in-trial value.

    Time frame: Week 0, Week 26

  23. Change in Mean Time to the IG Peak After Meal

    Change from baseline (week 0) in mean time to the IG peak after meal based on CGM was evaluated after 26 weeks of randomisation. A subgroup of subjects wore a CGM for between 11 and 13 days up to week 0 (randomisation) and up to week 26 to monitor their IG on a continuous basis. Presented values are mean of all the meals (breakfast, lunch and evening meal). The results are based on the last in-trial value.

    Time frame: Week 0, Week 26

  24. Change in 30-minute PPG

    Change from baseline (week 0) in 30-minute PPG based on meal test was evaluated after 26 weeks of randomisation. In connection to wearing the CGM for 11 to 13 days up to week 0 and up to week 26, the subgroup of participants had a standardised liquid meal test at the 2 visits, monitoring the PPG at 30-minute after the meal intake at the visit. The results are based on the last in-trial value.

    Time frame: Week 0, Week 26

  25. Change in 30-minute PPG Increment

    Change from baseline (week 0) in 30-minute PPG increment based on meal test was evaluated after 26 weeks of randomisation. In connection to wearing the CGM for 11 to 13 days up to week 0 and up to week 26, the subgroup of participants had a standardised liquid meal test at the 2 visits, monitoring the pre-prandial glucose (before the meal) the PPG at 30-minute (after the meal) at the visit. PPG increment was derived as 30-minute PPG measurement minus the pre-prandial PG. The results are based on the last in-trial value.

    Time frame: Week 0, Week 26

  26. Change in 1-hour PPG

    Change from baseline (week 0) in 1-hour PPG based on meal test was evaluated after 26 weeks of randomisation. In connection to wearing the CGM for 11 to 13 days up to week 0 and up to week 26, the subgroup of participants had a standardised liquid meal test at the 2 visits, monitoring the PPG at 1-hour after the meal intake at the visit. The results are based on the last in-trial value.

    Time frame: Week 0, Week 26

  27. Change in 1-hour PPG Increment

    Change from baseline (week 0) in 1-hour PPG increment based on meal test was evaluated after 26 weeks of randomisation. In connection to wearing the CGM for 11 to 13 days up to week 0 and up to week 26, the subgroup of participants had a standardised liquid meal test at the 2 visits, monitoring the pre-prandial glucose (before the meal) the PPG at 1-hour (after the meal) at the visit. PPG increment was derived as 1-hour PPG measurement minus the pre-prandial PG. The results are based on the last in-trial value.

    Time frame: Week 0, Week 26

  28. Change in 2-hour PPG

    Change from baseline (week 0) in 2-hour PPG based on meal test was evaluated after 26 weeks of randomisation. In connection to wearing the CGM for 11 to 13 days up to week 0 and up to week 26, the subgroup of participants had a standardised liquid meal test at the 2 visits, monitoring the PPG at 2-hour after the meal intake at the visit. The results are based on the last in-trial value.

    Time frame: Week 0, Week 26

  29. Change in 2-hour PPG Increment

    Change from baseline (week 0) in 2-hour PPG increment based on meal test was evaluated after 26 weeks of randomisation. In connection to wearing the CGM for 11 to 13 days up to week 0 and up to week 26, the subgroup of participants had a standardised liquid meal test at the 2 visits, monitoring the pre-prandial glucose (before the meal) the PPG at 2-hour (after the meal) at the visit. PPG increment was derived as 2-hour PPG measurement minus the pre-prandial PG. The results are based on the last in-trial value.

    Time frame: Week 0, Week 26

  30. Change in AUCIG,0-15min

    Change in area under the IG curve 0-15 minutes post meal (AUCIG,0-15min) during meal test and based on CGM measurements was evaluated after 26 weeks of randomisation. Interstitial glucose (IG) was measured every 5 minutes. The endpoint was calculated as the area under the IG curve using the trapezoidal method and weighted by duration. A subgroup of participants wore a CGM for between 11 and 13 days up to week 0 (randomisation) and up to week 26 to monitor their IG on a continuous basis. The results are based on the last in-trial value.

    Time frame: Week 0, Week 26

  31. Change in AUCIG,0-30min

    Change in area under the IG curve 0-30 minutes post meal (AUCIG,0-30min) during meal test and based on CGM measurements was evaluated after 26 weeks of randomisation. IG was measured every 5 minutes. The endpoint was calculated as the area under the IG curve using the trapezoidal method and weighted by duration. A subgroup of participants wore a CGM for between 11 and 13 days up to week 0 (randomisation) and up to week 26 to monitor their IG on a continuous basis. The results are based on the last in-trial value.

    Time frame: Week 0, Week 26

  32. Change in AUCIG,0-1h

    Change in area under the IG curve 0-1 hour post meal (AUCIG,0-1h) during meal test and based on CGM measurements was evaluated after 26 weeks of randomisation. IG was measured every 5 minutes. The endpoint was calculated as the area under the IG curve using the trapezoidal method and weighted by duration. A subgroup of participants wore a CGM for between 11 and 13 days up to week 0 (randomisation) and up to week 26 to monitor their IG on a continuous basis. The results are based on the last in-trial value.

    Time frame: Week 0, Week 26

  33. Change in AUCIG,0-2h

    Change in area under the IG curve 0-2 hours post meal (AUCIG,0-2h) during meal test and based on CGM measurements was evaluated after 26 weeks of randomisation. IG was measured every 5 minutes. The endpoint was calculated as the area under the IG curve using the trapezoidal method and weighted by duration. A subgroup of participants wore a CGM for between 11 and 13 days up to week 0 (randomisation) and up to week 26 to monitor their IG on a continuous basis. The results are based on the last in-trial value.

    Time frame: Week 0, Week 26

  34. Change in AUCIG,0-4h

    Change in area under the IG curve 0-4 hours post meal (AUCIG,0-4h) during meal test and based on CGM measurements was evaluated after 26 weeks of randomisation. IG was measured every 5 minutes. The endpoint was calculated as the area under the IG curve using the trapezoidal method and weighted by duration. A subgroup of participants wore a CGM for between 11 and 13 days up to week 0 (randomisation) and up to week 26 to monitor their IG on a continuous basis. The results are based on the last in-trial value.

    Time frame: Week 0, Week 26

  35. Change in Time to the IG Peak After Start of Meal

    Change in time to the IG peak after start of meal during meal test and based on CGM measurements was evaluated after 26 weeks of randomisation. A subgroup of participants wore a CGM for between 11 and 13 days up to week 0 (randomisation) and up to week 26 to monitor their IG on a continuous basis. Presented values are mean of all the meals (breakfast, lunch and evening meal). The results are based on the last in-trial value.

    Time frame: Week 0, Week 26

  36. Change in IG Peak After Start of Meal

    Change in IG peak after start of meal during meal test and based on CGM measurements was evaluated after 26 weeks of randomisation. A subgroup of participants wore a CGM for between 11 and 13 days up to week 0 (randomisation) and up to week 26 to monitor their IG on a continuous basis. Presented values are mean of all the meals (breakfast, lunch and evening meal). The results are based on the last in-trial value.

    Time frame: Week 0, Week 26

  37. Number of Treatment Emergent Hypoglycaemic Episodes According to American Diabetes Association (ADA)/ISPAD Classification: Total

    Treatment emergent: if the onset of the episode occurred on or after the first day of treatment with investigational medicinal product (IMP) after randomisation, and no later than 1 day after the last day on IMP. Classification of hypoglycaemia: 1) Severe (according to ISPAD classification). Following are according to ADA classification: 2) Documented symptomatic: episode during which typical symptoms of hypoglycaemia are accompanied by a PG level ≤3.9 mmol/L. 3) Asymptomatic: episode not accompanied by typical symptoms of hypoglycaemia, but with a PG level ≤3.9 mmol/L. 4) Probable symptomatic: an episode during which symptoms of hypoglycaemia are not accompanied by a PG determination but that was presumably caused by a PG level ≤3.9 mmol/L. 5) Pseudo-hypoglycaemia: episode during which the person with diabetes reports any of the typical symptoms of hypoglycaemia with a PG level \>3.9mmol/L, but approaching that level. The results are based on the on-treatment period.

    Time frame: Week 0-26

  38. Number of Treatment Emergent Hypoglycaemic Episodes According to ADA/ISPAD Classification: Daytime

    Classification of hypoglycaemia: 1) Severe (according to ISPAD classification). Following are according to ADA classification: 2) Documented symptomatic. 3) Asymptomatic. 4) Probable symptomatic. 5) Pseudo-hypoglycaemia. Daytime period: The period between 07:01 and 22:59 (both included). The results are based on the on-treatment period.

    Time frame: Week 0-26

  39. Number of Treatment Emergent Hypoglycaemic Episodes According to ADA/ISPAD Classification: Nocturnal (23:00-7:00, Both Included)

    Classification of hypoglycaemia: 1) Severe (according to ISPAD classification). Following are according to ADA classification: 2) Documented symptomatic. 3) Asymptomatic. 4) Probable symptomatic. 5) Pseudo-hypoglycaemia. Nocturnal period: The period between 23:00 and 07:00 (both included). The results are based on the on-treatment period.

    Time frame: Week 0-26

  40. Number of Treatment Emergent Hypoglycaemic Episodes According to Novo Nordisk/ISPAD Classification: Total

    Classification of hypoglycaemia: 1) Severe (according to ISPAD classification). Following are according to Novo Nordisk classification: 2) Symptomatic blood glucose (BG) confirmed: episode that is BG confirmed by PG value \<3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. 3) Asymptomatic BG confirmed: episode that is BG confirmed by PG value \<3.1 mmol/L without symptoms consistent with hypoglycaemia. 4) Severe or BG confirmed symptomatic: an episode that is severe according to the ISPAD classification or BG confirmed by a PG value \<3.1 mmol/L with symptoms consistent with hypoglycaemia. 5) BG confirmed: an episode that is BG confirmed by a PG value \<3.1 mmol/L with or without symptoms consistent with hypoglycaemia. 6) Severe or BG confirmed: an episode that is severe according to the ISPAD Classification or BG confirmed by a PG value \<3.1 mmol/L with or without symptoms consistent with hypoglycaemia. The results are based on the on-treatment period.

    Time frame: Week 0-26

  41. Number of Treatment Emergent Hypoglycaemic Episodes According to Novo Nordisk/ISPAD Classification: Daytime

    Classification of hypoglycaemia: 1) Severe (according to ISPAD classification). Following are according to Novo Nordisk classification: 2) BG confirmed. 3) Severe or BG confirmed symptomatic. 4) Severe or BG confirmed. 5) Asymptomatic BG confirmed. Daytime period: The period between 07:01 and 22:59 (both included). The results are based on the on-treatment period.

    Time frame: Week 0-26

  42. Number of Treatment Emergent Hypoglycaemic Episodes According to Novo Nordisk/ISPAD Classification: Nocturnal (23:00-7:00, Both Included)

    Classification of hypoglycaemia: 1) Severe (according to ISPAD classification). Following are according to Novo Nordisk classification: 2) BG confirmed. 3) Severe or BG confirmed symptomatic. 4) Severe or BG confirmed. 5) Asymptomatic BG confirmed. Nocturnal period: The period between 23:00 and 07:00 (both included). The results are based on the on-treatment period.

    Time frame: Week 0-26

  43. Number of Treatment Emergent Meal Related (From Start of Meal Until 1 Hour After Start of Meal) Hypoglycaemic Episodes According to ADA/ISPAD Classification

    Classification of hypoglycaemia: 1) Severe (according to ISPAD classification). Following are according to ADA classification: 2) Documented symptomatic. 3) Asymptomatic. 4) Probable symptomatic. 5) Pseudo-hypoglycaemia. The results are based on the on-treatment period.

    Time frame: Week 0-26

  44. Number of Treatment Emergent Meal Related (From Start of Meal Until 2 Hours After Start of Meal) Hypoglycaemic Episodes According to ADA/ISPAD Classification

    Classification of hypoglycaemia: 1) Severe (according to ISPAD classification). Following are according to ADA classification: 2) Documented symptomatic. 3) Asymptomatic. 4) Probable symptomatic. 5) Pseudo-hypoglycaemia. The results are based on the on-treatment period.

    Time frame: Week 0-26

  45. Number of Treatment Emergent Meal Related (From Start of Meal Until 4 Hours After Start of Meal) Hypoglycaemic Episodes According to ADA/ISPAD Classification

    Classification of hypoglycaemia: 1) Severe (according to ISPAD classification). Following are according to ADA classification: 2) Documented symptomatic. 3) Asymptomatic. 4) Probable symptomatic. 5) Pseudo-hypoglycaemia. The results are based on the on-treatment period.

    Time frame: Week 0-26

  46. Number of Treatment Emergent Meal Related (From 2-4 Hours After Start of Meal) Hypoglycaemic Episodes According to ADA/ISPAD Classification

    Classification of hypoglycaemia: 1) Severe (according to ISPAD classification). Following are according to ADA classification: 2) Documented symptomatic. 3) Asymptomatic. 4) Probable symptomatic. 5) Pseudo-hypoglycaemia. The results are based on the on-treatment period.

    Time frame: Week 0-26

  47. Number of Treatment Emergent Meal Related (From Start of Meal Until 1 Hour After Start of Meal) Hypoglycaemic Episodes According to Novo Nordisk/ISPAD Classification

    Classification of hypoglycaemia: 1) Severe (according to ISPAD classification). Following are according to Novo Nordisk classification: 2) BG confirmed. 3) Severe or BG confirmed symptomatic. 4) Severe or BG confirmed. 5) Asymptomatic BG confirmed. The results are based on the on-treatment period.

    Time frame: Week 0-26

  48. Number of Treatment Emergent Meal Related (From Start of Meal Until 2 Hours After Start of Meal) Hypoglycaemic Episodes According to Novo Nordisk/ISPAD Classification

    Classification of hypoglycaemia: 1) Severe (according to ISPAD classification). Following are according to Novo Nordisk classification: 2) BG confirmed. 3) Severe or BG confirmed symptomatic. 4) Severe or BG confirmed. 5) Asymptomatic BG confirmed. The results are based on the on-treatment period.

    Time frame: Week 0-26

  49. Number of Treatment Emergent Meal Related (From Start of Meal Until 4 Hours After Start of Meal) Hypoglycaemic Episodes According to Novo Nordisk/ISPAD Classification

    Classification of hypoglycaemia: 1) Severe (according to ISPAD classification). Following are according to Novo Nordisk classification: 2) BG confirmed. 3) Severe or BG confirmed symptomatic. 4) Severe or BG confirmed. 5) Asymptomatic BG confirmed. The results are based on the on-treatment period.

    Time frame: Week 0-26

  50. Number of Treatment Emergent Meal Related (From 2-4 Hours After Start of Meal) Hypoglycaemic Episodes According to Novo Nordisk/ISPAD Classification

    Classification of hypoglycaemia: 1) Severe (according to ISPAD classification). Following are according to Novo Nordisk classification: 2) BG confirmed. 3) Severe or BG confirmed symptomatic. 4) Severe or BG confirmed. 5) Asymptomatic BG confirmed. The results are based on the on-treatment period.

    Time frame: Week 0-26

  51. Number of Treatment Emergent Adverse Events (AEs)

    Treatment emergent was defined as an event that has onset up to 7 days after last day of IMP (faster aspart or NovoRapid®/NovoLog®) and excluding the events occurring in the run-in period. The results are based on the on-treatment period.

    Time frame: Week 0-26

  52. Number of Treatment Emergent Injection Site Reactions

    Treatment emergent was defined as an event that has onset up to 7 days after last day of IMP and excluding the events occurring in the run-in period. The results are based on the on-treatment period.

    Time frame: Week 0-26

  53. Change in Physical Examination

    The following physical examinations were done: 1) Cardiovascular system. 2) Central and peripheral nervous system. 3) Gastrointestinal system including the mouth. 4) General appearance. 5) Head, ears, eyes, nose, throat and neck. 6) Musculoskeletal system. 7) Respiratory system. 8) Skin. Presented results are number of participants with the following outcomes: normal, abnormal not clinically significant (NCS) and abnormal clinically significant (CS). Presented results are baseline (week 0) and last on-treatment values. Number of participants analysed = number of participants contributed to the analysis.

    Time frame: Week 0, Week 26

  54. Change in Vital Sign: Blood Pressure

    Change from baseline (week 0) in blood pressure (systolic blood pressure (SBP) and diastolic blood pressure (DBP)) was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value.

    Time frame: Week 0, Week 26

  55. Change in Vital Sign: Pulse

    Change from baseline (week 0) in pulse was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value.

    Time frame: Week 0, Week 26

  56. Change in Body Weight

    Change from baseline (week 0) in body weight was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.

    Time frame: Week 0, Week 26

  57. Change in Height

    Change from baseline (week 0) in height was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.

    Time frame: Week 0, Week 26

  58. Change in Body Mass Index

    Change from baseline (week 0) in body mass index (BMI) was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.

    Time frame: Week 0, Week 26

  59. Change in SD Score of Body Weight

    Change from baseline (week 0) in standard deviation (SD) score of body weight was evaluated after 26 weeks of randomisation. SD-scores are defined to be able to normalise the body weight in the various age groups. To estimate the growth of children, standardised weight is calculated for each year of age and for each sex. Thus, a child with a weight equal to the mean value for its age and sex has an SD score of 0, while a child with a weight 2 SDs above the mean value for its age and sex has an SD score of +2. The SD scores are derived from the age and sex of the subjects and the body weight together with growth curves defined for a reference population. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.

    Time frame: Week 0, Week 26

  60. Change in SD Score of Body Mass Index

    Change from baseline (week 0) in SD score of BMI was evaluated after 26 weeks of randomisation. SD scores for BMI were determined in a similar way as SD scores for weight by use of a suitable reference population based on age and sex. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.

    Time frame: Week 0, Week 26

  61. Change in Haematology: Haemoglobin

    Change from baseline (week 0) in haemoglobin was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.

    Time frame: Week 0, Week 26

  62. Change in Haematology: Haematocrit

    Change from baseline (week 0) in haematocrit was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.

    Time frame: Week 0, Week 26

  63. Change in Haematology: Erythrocytes

    Change from baseline (week 0) in erythrocytes was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.

    Time frame: Week 0, Week 26

  64. Change in Haematology: Thrombocytes

    Change from baseline (week 0) in thrombocytes was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.

    Time frame: Week 0, Week 26

  65. Change in Haematology: Leukocytes

    Change from baseline (week 0) in leukocytes was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.

    Time frame: Week 0, Week 26

  66. Change in Biochemistry: Creatinine

    Change from baseline (week 0) in creatinine was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.

    Time frame: Week 0, Week 26

  67. Change in Biochemistry: Alanine Aminotransferase (ALT)

    Change from baseline (week 0) in ALT was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.

    Time frame: Week 0, Week 26

  68. Change in Biochemistry: Aspartate Aminotransferase (AST)

    Change from baseline (week 0) in AST was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.

    Time frame: Week 0, Week 26

  69. Change in Biochemistry: Alkaline Phosphatase (AP)

    Change from baseline (week 0) in AP was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.

    Time frame: Week 0, Week 26

  70. Change in Biochemistry: Sodium

    Change from baseline (week 0) in sodium was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.

    Time frame: Week 0, Week 26

  71. Change in Biochemistry: Potassium

    Change from baseline (week 0) in potassium was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.

    Time frame: Week 0, Week 26

  72. Change in Biochemistry: Albumin

    Change from baseline (week 0) in albumin was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.

    Time frame: Week 0, Week 26

  73. Change in Biochemistry: Total Bilirubin

    Change from baseline (week 0) in total bilirubin was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.

    Time frame: Week 0, Week 26

  74. Change in Lipid Profile: Total Cholesterol

    Change from baseline (week 0) in total cholesterol after 26 weeks of randomisation is presented as ratio to baseline values. The results are based on the last on-treatment value.

    Time frame: Week 0, Week 26

  75. Change in Lipid Profile: High Density Lipoproteins (HDL)

    Change from baseline (week 0) in HDL after 26 weeks of randomisation is presented as ratio to baseline values. The results are based on the last on-treatment value.

    Time frame: Week 0, Week 26

  76. Change in Lipid Profile: Low Density Lipoproteins (LDL)

    Change from baseline (week 0) in LDL after 26 weeks of randomisation is presented as ratio to baseline values. The results are based on the last on-treatment value.

    Time frame: Week 0, Week 26

  77. Change in Anti-insulin Aspart Antibody Development: Specific

    Change from baseline (week 0) in 'antibodies specific for insulin aspart' was evaluated after 26 weeks of randomisation. This endpoint was measured as % bound radioactivity-labelled insulin aspart/Total added radioactivity-labelled insulin aspart (%B/T). The results are based on the last on-treatment value.

    Time frame: Week 0, Week 26

  78. Change in Anti-insulin Aspart Antibody Development: Cross-reacting With Human Insulin

    Change from baseline (week 0) in 'antibodies for insulin aspart, those cross-reacting with human insulin' was evaluated after 26 weeks of randomisation. This endpoint was measured as % bound radioactivity-labelled insulin aspart/Total added radioactivity-labelled insulin aspart (%B/T). The results are based on the last on-treatment value.

    Time frame: Week 0, Week 26

  79. Change in Anti-insulin Aspart Antibody Development: Total

    Change from baseline (week 0) in 'total anti-insulin aspart antibodies (specific for insulin aspart and those cross-reacting with human insulin)' was evaluated after 26 weeks of randomisation. This endpoint was measured as % bound radioactivity-labelled insulin aspart/Total added radioactivity-labelled insulin aspart (%B/T). The results are based on the last on-treatment value.

    Time frame: Week 0, Week 26

08

Results

Posted Apr 4, 2019

Participant flow

The trial was conducted at 150 sites in 17 countries(number of sites with screened/randomised subjects)-Bulgaria: 4/4; Czech Republic: 6/6; Estonia: 2/2; Finland: 3/3; Germany: 6/6; India: 7/7; Israel: 6/6; Italy: 5/5; Japan: 34/34; Latvia: 1/1; Lithuania: 1/1; Poland: 4/4; Russia: 11/11; Serbia: 4/4; Turkey: 7/7; Ukraine: 9/9; United States: 40/39

Participant flow — Overall Study
MilestoneFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Started260259258
Completed256251253
Not completed485
Withdrew: Withdrawal by subject014
Withdrew: Withdrawal by parent/guardian441
Withdrew: Unclassified030

Outcome measures

PrimaryChange in the Percentage of HbA1c

Change from baseline (week 0) in glycosylated haemoglobin (HbA1c) was evaluated after 26 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In-trial period: the observation period from date of randomisation until last trial-related participant-site contact and included data collected after a subject discontinued trial product.

Time frame:
Week 0, Week 26
Reported as:
Mean · Percentage of HbA1c
Change in the Percentage of HbA1c
Percentage of HbA1cFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Baseline7.57 ± 0.807.58 ± 0.847.53 ± 0.83
Change from baseline0.06 ± 0.800.33 ± 0.830.23 ± 0.82
Statistical analysis
  • Faster Aspart (Meal) vs NovoRapid (Meal) · Multiple imputation · p = <0.001 (p-values are from the 1-sided test for non-inferiority evaluated at the 2.5% level.) · Treatment difference: -0.17 · 95% CI -0.30 to -0.03Analyses were adjusted for region, strata (age), as factors, and baseline HbA1c as a covariate.
  • Faster Aspart (Post) vs NovoRapid (Meal) · Multiple imputation · p = <0.001 (p-values are from the 1-sided test for non-inferiority evaluated at the 2.5% level.) · Treatment difference: 0.13 · 95% CI -0.01 to 0.26Analyses were adjusted for region, strata (age), as factors, and baseline HbA1c as a covariate.
  • Faster Aspart (Meal) vs NovoRapid (Meal) · multiple imputation · p = =0.007 (p-values are from the 1-sided test for superiority evaluated at the 2.5% level.) · Treatment difference: -0.17 · 95% CI -0.30 to -0.03Analyses were adjusted for region, strata (age), as factors, and baseline HbA1c as a covariate.
SecondaryChange in 8-point SMPG Profile: Mean PPG Over All Three Meals

Change from baseline (week 0) in mean post prandial glucose (PPG) over all three meals was evaluated after 26 weeks of randomisation. PPG for each meal (breakfast, lunch and main evening meal) was recorded by the participant as part of the 8-point self-measured plasma glucose (SMPG) profile. Mean PPG over all three meals was derived as the mean of all corresponding mean meal. The results are based on the last in-trial value.

Time frame:
Week 0, Week 26
Reported as:
Mean · mmol/L
Change in 8-point SMPG Profile: Mean PPG Over All Three Meals
mmol/LFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Baseline10.19 ± 2.6410.12 ± 2.7910.03 ± 2.52
Change from baseline-0.94 ± 2.550.36 ± 3.17-0.21 ± 2.79
SecondaryChange in 8-point SMPG Profile: PPG Increment Over All Three Meals

Change from baseline (week 0) in mean PPG increment over all three meals was evaluated after 26 weeks of randomisation. Postprandial glucose (PPG) increment for each meal (breakfast, lunch and main evening meal) was derived from the 8-point profile as the difference between PPG (1 hour after the meal) values and the plasma glucose (PG) value before meal. The mean of the derived increments was then calculated separately for each meal. Mean PPG increment over all three meals was derived as the mean of all corresponding mean meal increments. The results are based on the last in-trial value.

Time frame:
Week 0, Week 26
Reported as:
Mean · mmol/L
Change in 8-point SMPG Profile: PPG Increment Over All Three Meals
mmol/LFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Baseline1.20 ± 2.701.01 ± 2.480.97 ± 2.55
Change from baseline-0.92 ± 2.920.56 ± 2.880.14 ± 2.75
SecondaryChange in 8-point SMPG Profile: Individual Meal (Breakfast, Lunch and Main Evening Meal) PPG

Change from baseline (week 0) in individual meal (breakfast, lunch and main evening meal) PPG was evaluated after 26 weeks of randomisation. PPG for each meal was recorded by the participant as part of the 8-point SMPG profile. The results are based on the last in-trial value.

Time frame:
Week 0, Week 26
Reported as:
Mean · mmol/L
Change in 8-point SMPG Profile: Individual Meal (Breakfast, Lunch and Main Evening Meal) PPG
mmol/LFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Breakfast: Baseline10.51 ± 3.5910.51 ± 3.7710.49 ± 3.59
Breakfast: Change from baseline-1.11 ± 3.910.16 ± 3.950.04 ± 3.89
Lunch: Baseline9.69 ± 3.329.99 ± 3.829.62 ± 3.30
Lunch: Change from baseline-0.80 ± 3.740.18 ± 4.40-0.24 ± 4.22
Main evening meal: Baseline10.24 ± 3.649.90 ± 3.599.87 ± 3.46
Main evening meal: Change from baseline-0.74 ± 3.960.61 ± 4.40-0.05 ± 4.14
SecondaryChange in 8-point SMPG Profile: Individual Meal (Breakfast, Lunch and Main Evening Meal) PPG Increment

Change from baseline (week 0) in individual meal (breakfast, lunch and main evening meal) PPG increment was evaluated after 26 weeks of randomisation. PPG increment for each meal was derived from the 8-point profile as the difference between PPG values (1 hour after the meal) and the PG value before meal. The results are based on the last in-trial value.

Time frame:
Week 0, Week 26
Reported as:
Mean · mmol/L
Change in 8-point SMPG Profile: Individual Meal (Breakfast, Lunch and Main Evening Meal) PPG Increment
mmol/LFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Breakfast: Baseline1.90 ± 3.642.10 ± 3.592.12 ± 4.08
Breakfast: Change from baseline-0.82 ± 4.440.46 ± 4.210.10 ± 4.66
Lunch: Baseline1.02 ± 3.821.12 ± 3.790.74 ± 3.88
Lunch: Change from baseline-0.58 ± 4.920.12 ± 4.41-0.11 ± 4.54
Main evening meal: Baseline0.53 ± 4.28-0.26 ± 3.53-0.06 ± 3.78
Main evening meal: Change from baseline-0.92 ± 5.071.03 ± 4.680.45 ± 4.31
SecondaryChange in 8-point SMPG Profile: Mean of the 8-point Profile

Change from baseline (week 0) in mean of the 8-point SMPG profile was evaluated after 26 weeks of randomisation. SMPG values were recorded at 8 time-points on two consecutive days: before and after (60 minute after the start of the meal) breakfast, lunch and main evening meal, before bedtime, and before breakfast on the next day. Mean of the 8-point profile was derived as the mean of all corresponding mean SMPG recorded at 8 different time points. The results are based on the last in-trial value.

Time frame:
Week 0, Week 26
Reported as:
Mean · mmol/L
Change in 8-point SMPG Profile: Mean of the 8-point Profile
mmol/LFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Baseline9.41 ± 1.989.47 ± 1.899.39 ± 1.97
Change from baseline-0.27 ± 2.040.17 ± 2.12-0.05 ± 2.29
SecondaryFluctuation in the 8-point SMPG Profile

Fluctuation in the 8-point SMPG profile was evaluated after 26 weeks of randomisation. Fluctuation in 8-point SMPG profile was the average absolute difference from the mean of the SMPG profile. The results are based on the last in-trial value.

Time frame:
Week 26
Reported as:
Geometric mean · mmol/L
Fluctuation in the 8-point SMPG Profile
mmol/LFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Fluctuation in the 8-point SMPG Profile1.88 ± 44.491.94 ± 42.511.83 ± 45.98
SecondaryChange in FPG

Change from baseline (week 0) in fasting plasma glucose (FPG) was evaluated after 26 weeks of randomisation. The results are based on the last in-trial value.

Time frame:
Week 0, Week 26
Reported as:
Mean · mmol/L
Change in FPG
mmol/LFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Baseline7.58 ± 3.568.03 ± 3.357.79 ± 3.48
Change from baseline0.41 ± 5.04-0.08 ± 4.49-0.13 ± 4.16
SecondaryChange in 1,5-anhydroglucitol

Change from baseline (week 0) in 1,5-anhydroglucitol was evaluated after 26 weeks of randomisation. The results are based on the last in-trial value.

Time frame:
Week 0, Week 26
Reported as:
Mean · ug/mL
Change in 1,5-anhydroglucitol
ug/mLFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Baseline4.95 ± 3.625.07 ± 3.975.13 ± 3.76
Change from baseline-0.06 ± 3.13-0.85 ± 2.80-0.63 ± 2.42
SecondaryPercentage of Subjects Reaching HbA1c Target (HbA1c Less Than 7.5 %) According to ISPAD Guidelines

Percentage of participants (yes/no) reaching HbA1c less than 7.5 % according to International Society for Pediatric and Adolescent Diabetes (ISPAD) guidelines was evaluated after 26 weeks of randomisation. The results are based on the last in-trial value.

Time frame:
Week 26
Reported as:
Number · Percentage of participants
Percentage of Subjects Reaching HbA1c Target (HbA1c Less Than 7.5 %) According to ISPAD Guidelines
Percentage of participantsFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Yes42.331.739.5
No57.768.360.5
SecondaryPercentage of Subjects Reaching HbA1c Target (HbA1c Less Than 7.5 %) According to ISPAD Guidelines, Without Severe Hypoglycaemia

Percentage of participants (yes/no) reaching HbA1c less than 7.5 % according to ISPAD guidelines, without severe hypoglycaemia was evaluated after 26 weeks of randomisation. Severe hypoglycaemia according to ISPAD guidelines: hypoglycaemic episode associated with severe neuroglycopenia, usually resulting in coma or seizure and requiring parenteral therapy (glucagon or intravenous glucose). The results are based on the last in-trial value.

Time frame:
Week 26
Reported as:
Number · Percentage of participants
Percentage of Subjects Reaching HbA1c Target (HbA1c Less Than 7.5 %) According to ISPAD Guidelines, Without Severe Hypoglycaemia
Percentage of participantsFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Yes41.930.938.4
No58.169.161.6
SecondaryInsulin Dose (Units/Day): Total Basal

Total basal insulin dose (Units/day) was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period: the observation period from date of first dose of randomised NovoRapid®/NovoLog® / faster aspart and no later than 7 days after the day of last dose of NovoRapid®/NovoLog® / faster aspart. The on-treatment observation period includes data collected up to and including 7 days after treatment discontinuation. Number of participants analysed = number of participants contributed to the analysis. Analysis population description: Safety analysis set (SAS) included all participants receiving at least one dose of the investigational product (faster aspart) or its comparator (NovoRapid®/NovoLog®).

Time frame:
Week 26
Reported as:
Mean · Units (U)
Insulin Dose (Units/Day): Total Basal
Units (U)Faster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Insulin Dose (Units/Day): Total Basal21.6 ± 12.921.5 ± 14.520.7 ± 12.8
SecondaryInsulin Dose (Units/Day): Total Bolus

Total bolus insulin dose (Units/day) was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.

Time frame:
Week 26
Reported as:
Mean · Units (U)
Insulin Dose (Units/Day): Total Bolus
Units (U)Faster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Insulin Dose (Units/Day): Total Bolus23.3 ± 14.523.5 ± 15.122.5 ± 13.0
SecondaryInsulin Dose (Units/Day): Individual Meal Insulin Dose

Individual meal (breakfast, lunch and main evening meal) insulin dose (Units/day) was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value.

Time frame:
Week 26
Reported as:
Mean · Units (U)
Insulin Dose (Units/Day): Individual Meal Insulin Dose
Units (U)Faster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Breakfast7.3 ± 5.17.1 ± 4.96.8 ± 4.4
Lunch8.1 ± 5.18.4 ± 6.27.9 ± 5.2
Main evening meal8.1 ± 6.08.0 ± 5.47.7 ± 5.1
SecondaryInsulin Dose (Units/kg/Day): Total Basal

Total basal insulin dose (Units/kg/day) was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.

Time frame:
Week 26
Reported as:
Mean · Units (U)/kg
Insulin Dose (Units/kg/Day): Total Basal
Units (U)/kgFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Insulin Dose (Units/kg/Day): Total Basal0.433 ± 0.2280.425 ± 0.1960.409 ± 0.176
SecondaryInsulin Dose (Units/kg/Day): Total Bolus

Total bolus insulin dose (Units/kg/day) was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.

Time frame:
Week 26
Reported as:
Mean · Units (U)/kg
Insulin Dose (Units/kg/Day): Total Bolus
Units (U)/kgFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Insulin Dose (Units/kg/Day): Total Bolus0.483 ± 0.2560.491 ± 0.2410.468 ± 0.224
SecondaryInsulin Dose (Units/kg/Day): Individual Meal Insulin Dose

Individual meal (breakfast, lunch and main evening meal) insulin dose (Units/kg/day) was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.

Time frame:
Week 26
Reported as:
Mean · Units (U)/kg
Insulin Dose (Units/kg/Day): Individual Meal Insulin Dose
Units (U)/kgFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Breakfast0.151 ± 0.0910.150 ± 0.0790.144 ± 0.081
Lunch0.170 ± 0.1030.174 ± 0.1040.166 ± 0.095
Main evening meal0.164 ± 0.0990.165 ± 0.0920.158 ± 0.086
SecondaryChange of Time Spent in Low Interstitial Glucose (IG) (IG <=3.9 mmol/L [70 mg/dL])

Change from baseline (week 0) in the time spent in low IG (\<=3.9 mmol/L \[70 mg/dL\]) based on continuous glucose monitoring (CGM) was evaluated after 26 weeks of randomisation. A subgroup of participants wore a CGM for between 11 and 13 days up to week 0 (randomisation) and up to week 26 to monitor their IG on a continuous basis. The results are based on the last in-trial value.

Time frame:
Week 0, Week 26
Reported as:
Mean · Minutes/day
Change of Time Spent in Low Interstitial Glucose (IG) (IG <=3.9 mmol/L [70 mg/dL])
Minutes/dayFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Baseline107.94 ± 77.34100.70 ± 77.2881.52 ± 71.90
Change from baseline-24.11 ± 71.74-13.06 ± 82.556.92 ± 74.64
SecondaryIncidence of Episodes With IG <=2.5, 3.0, 3.9 mmol/L (45, 54, 70 mg/dL) and IG >10.0, 12.0 mmol/L (180, 216 mg/dL)

Incidence of episodes (number of episodes per 24 hours) with IG \<=2.5, 3.0, 3.9 mmol/L (45, 54, 70 mg/dL) and IG \>10.0, 12.0 mmol/L (180, 216 mg/dL) based on CGM was calculated after 26 weeks of randomisation. A subgroup of participants wore a CGM for between 11 and 13 days up to week 0 (randomisation) and up to week 26 to monitor their IG on a continuous basis. The results are based on the last in-trial value.

Time frame:
Week 26
Reported as:
Number · Episodes per 24 hours
Incidence of Episodes With IG <=2.5, 3.0, 3.9 mmol/L (45, 54, 70 mg/dL) and IG >10.0, 12.0 mmol/L (180, 216 mg/dL)
Episodes per 24 hoursFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Episodes with IG <=2.5 mmol/L0.550.680.57
Episodes with IG <=3.0 mmol/L1.011.101.03
Episodes with IG <=3.9 mmol/L2.292.302.24
Episodes with IG >10 mmol/L11.5211.6111.65
Episodes with IG >12 mmol/L7.647.778.05
SecondaryPercentage of Time Spent With IG <=2.5, 3.0, 3.9 mmol/L (45, 54, 70 mg/dL) and IG >10.0, 12.0 mmol/L (180, 216 mg/dL)

Percentage of time spent with IG \<=2.5, 3.0, 3.9 mmol/L (45, 54, 70 mg/dL) and IG \>10.0, 12.0 mmol/L (180, 216 mg/dL) based on CGM was evaluated after 26 weeks of randomisation. A subgroup of participants wore a CGM for between 11 and 13 days up to week 0 (randomisation) and up to week 26 to monitor their IG on a continuous basis. The results are based on the last in-trial value.

Time frame:
Week 26
Reported as:
Mean · Percentage of time
Percentage of Time Spent With IG <=2.5, 3.0, 3.9 mmol/L (45, 54, 70 mg/dL) and IG >10.0, 12.0 mmol/L (180, 216 mg/dL)
Percentage of timeFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Time spent with IG <=2.5 mmol/L1.09 ± 1.501.80 ± 3.211.34 ± 1.90
Time spent with IG <=3.0 mmol/L2.19 ± 2.352.90 ± 4.062.48 ± 2.92
Time spent with IG <=3.9 mmol/L5.97 ± 4.596.25 ± 5.685.97 ± 5.38
Time spent with IG >10 mmol/L40.40 ± 14.8040.60 ± 14.3842.47 ± 17.51
Time spent with IG >12 mmol/L26.09 ± 12.8225.67 ± 13.6028.62 ± 16.83
SecondaryPercentage of Time Spent Within IG Target 4.0-10.0 mmol/L (71-180 mg/dL) Both Included

Percentage of time spent within IG target 4.0-10.0 mmol/L (71-180 mg/dL), both included based on CGM was evaluated after 26 weeks of randomisation. A subgroup of participants wore a CGM for between 11 and 13 days up to week 0 (randomisation) and up to week 26 to monitor their IG on a continuous basis. The results are based on the last in-trial value.

Time frame:
Week 26
Reported as:
Mean · Percentage of time
Percentage of Time Spent Within IG Target 4.0-10.0 mmol/L (71-180 mg/dL) Both Included
Percentage of timeFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Percentage of Time Spent Within IG Target 4.0-10.0 mmol/L (71-180 mg/dL) Both Included53.00 ± 12.1552.56 ± 14.0851.03 ± 16.25
SecondaryChange in Mean IG Increment (0-1 Hours and 0-2 Hours After Start of the Meal)

Change from baseline (week 0) in mean IG increment (0-1 hours and 0-2 hours after start of the meal) based on CGM was evaluated after 26 weeks of randomisation. A subgroup of participants wore a CGM for between 11 and 13 days up to week 0 (randomisation) and up to week 26 to monitor their IG on a continuous basis. Presented values are mean of all the meals (breakfast, lunch and evening meal). The results are based on the last in-trial value.

Time frame:
Week 0, Week 26
Reported as:
Mean · mmol/L
Change in Mean IG Increment (0-1 Hours and 0-2 Hours After Start of the Meal)
mmol/LFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
0-1 hour: Baseline0.56 ± 0.580.73 ± 0.540.61 ± 0.49
0-1 hour: Change from baseline-0.19 ± 0.550.26 ± 0.830.07 ± 0.50
0-2 hour: Baseline0.76 ± 0.751.10 ± 1.030.86 ± 0.69
0-2 hour: Change from baseline-0.35 ± 0.870.55 ± 1.140.09 ± 0.59
SecondaryChange in Mean IG Peak After Start of Meal

Change from baseline (week 0) in mean IG peak after start of meal based on CGM was evaluated after 26 weeks of randomisation. A subgroup of participants wore a CGM for between 11 and 13 days up to week 0 (randomisation) and up to week 26 to monitor their IG on a continuous basis. Presented values are mean of all the meals (breakfast, lunch and evening meal). The results are based on the last in-trial value.

Time frame:
Week 0, Week 26
Reported as:
Mean · mmol/L
Change in Mean IG Peak After Start of Meal
mmol/LFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Baseline12.90 ± 1.8812.92 ± 1.9712.90 ± 2.25
Change from baseline-0.28 ± 1.910.80 ± 1.840.38 ± 2.00
SecondaryChange in Mean Time to the IG Peak After Meal

Change from baseline (week 0) in mean time to the IG peak after meal based on CGM was evaluated after 26 weeks of randomisation. A subgroup of subjects wore a CGM for between 11 and 13 days up to week 0 (randomisation) and up to week 26 to monitor their IG on a continuous basis. Presented values are mean of all the meals (breakfast, lunch and evening meal). The results are based on the last in-trial value.

Time frame:
Week 0, Week 26
Reported as:
Mean · Minutes
Change in Mean Time to the IG Peak After Meal
MinutesFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Baseline103.16 ± 16.87106.21 ± 20.68102.20 ± 17.09
Change from baseline4.70 ± 25.85-8.56 ± 22.622.29 ± 19.80
SecondaryChange in 30-minute PPG

Change from baseline (week 0) in 30-minute PPG based on meal test was evaluated after 26 weeks of randomisation. In connection to wearing the CGM for 11 to 13 days up to week 0 and up to week 26, the subgroup of participants had a standardised liquid meal test at the 2 visits, monitoring the PPG at 30-minute after the meal intake at the visit. The results are based on the last in-trial value.

Time frame:
Week 0, Week 26
Reported as:
Mean · mmol/L
Change in 30-minute PPG
mmol/LFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Baseline11.28 ± 3.2610.96 ± 3.7811.71 ± 3.13
Change from baseline-0.21 ± 3.491.84 ± 3.41-0.45 ± 3.42
SecondaryChange in 30-minute PPG Increment

Change from baseline (week 0) in 30-minute PPG increment based on meal test was evaluated after 26 weeks of randomisation. In connection to wearing the CGM for 11 to 13 days up to week 0 and up to week 26, the subgroup of participants had a standardised liquid meal test at the 2 visits, monitoring the pre-prandial glucose (before the meal) the PPG at 30-minute (after the meal) at the visit. PPG increment was derived as 30-minute PPG measurement minus the pre-prandial PG. The results are based on the last in-trial value.

Time frame:
Week 0, Week 26
Reported as:
Mean · mmol/L
Change in 30-minute PPG Increment
mmol/LFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Baseline3.44 ± 2.163.48 ± 2.504.02 ± 2.18
Change from baseline0.36 ± 2.921.92 ± 2.79-0.34 ± 2.18
SecondaryChange in 1-hour PPG

Change from baseline (week 0) in 1-hour PPG based on meal test was evaluated after 26 weeks of randomisation. In connection to wearing the CGM for 11 to 13 days up to week 0 and up to week 26, the subgroup of participants had a standardised liquid meal test at the 2 visits, monitoring the PPG at 1-hour after the meal intake at the visit. The results are based on the last in-trial value.

Time frame:
Week 0, Week 26
Reported as:
Mean · mmol/L
Change in 1-hour PPG
mmol/LFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Baseline12.77 ± 3.9212.56 ± 5.0813.06 ± 3.86
Change from baseline-0.15 ± 4.392.54 ± 4.43-0.63 ± 4.73
SecondaryChange in 1-hour PPG Increment

Change from baseline (week 0) in 1-hour PPG increment based on meal test was evaluated after 26 weeks of randomisation. In connection to wearing the CGM for 11 to 13 days up to week 0 and up to week 26, the subgroup of participants had a standardised liquid meal test at the 2 visits, monitoring the pre-prandial glucose (before the meal) the PPG at 1-hour (after the meal) at the visit. PPG increment was derived as 1-hour PPG measurement minus the pre-prandial PG. The results are based on the last in-trial value.

Time frame:
Week 0, Week 26
Reported as:
Mean · mmol/L
Change in 1-hour PPG Increment
mmol/LFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Baseline4.93 ± 3.345.08 ± 4.215.36 ± 2.77
Change from baseline0.42 ± 4.932.63 ± 4.03-0.52 ± 3.17
SecondaryChange in 2-hour PPG

Change from baseline (week 0) in 2-hour PPG based on meal test was evaluated after 26 weeks of randomisation. In connection to wearing the CGM for 11 to 13 days up to week 0 and up to week 26, the subgroup of participants had a standardised liquid meal test at the 2 visits, monitoring the PPG at 2-hour after the meal intake at the visit. The results are based on the last in-trial value.

Time frame:
Week 0, Week 26
Reported as:
Mean · mmol/L
Change in 2-hour PPG
mmol/LFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Baseline12.50 ± 4.6312.54 ± 5.7412.37 ± 4.74
Change from baseline0.69 ± 5.881.80 ± 5.08-0.75 ± 5.64
SecondaryChange in 2-hour PPG Increment

Change from baseline (week 0) in 2-hour PPG increment based on meal test was evaluated after 26 weeks of randomisation. In connection to wearing the CGM for 11 to 13 days up to week 0 and up to week 26, the subgroup of participants had a standardised liquid meal test at the 2 visits, monitoring the pre-prandial glucose (before the meal) the PPG at 2-hour (after the meal) at the visit. PPG increment was derived as 2-hour PPG measurement minus the pre-prandial PG. The results are based on the last in-trial value.

Time frame:
Week 0, Week 26
Reported as:
Mean · mmol/L
Change in 2-hour PPG Increment
mmol/LFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Baseline4.66 ± 4.225.06 ± 5.044.67 ± 3.83
Change from baseline1.26 ± 6.811.62 ± 5.03-0.64 ± 4.43
SecondaryChange in AUCIG,0-15min

Change in area under the IG curve 0-15 minutes post meal (AUCIG,0-15min) during meal test and based on CGM measurements was evaluated after 26 weeks of randomisation. Interstitial glucose (IG) was measured every 5 minutes. The endpoint was calculated as the area under the IG curve using the trapezoidal method and weighted by duration. A subgroup of participants wore a CGM for between 11 and 13 days up to week 0 (randomisation) and up to week 26 to monitor their IG on a continuous basis. The results are based on the last in-trial value.

Time frame:
Week 0, Week 26
Reported as:
Mean · mmol/L
Change in AUCIG,0-15min
mmol/LFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Baseline8.01 ± 2.727.49 ± 2.077.66 ± 1.96
Change from baseline-1.27 ± 3.680.08 ± 2.48-0.53 ± 2.85
SecondaryChange in AUCIG,0-30min

Change in area under the IG curve 0-30 minutes post meal (AUCIG,0-30min) during meal test and based on CGM measurements was evaluated after 26 weeks of randomisation. IG was measured every 5 minutes. The endpoint was calculated as the area under the IG curve using the trapezoidal method and weighted by duration. A subgroup of participants wore a CGM for between 11 and 13 days up to week 0 (randomisation) and up to week 26 to monitor their IG on a continuous basis. The results are based on the last in-trial value.

Time frame:
Week 0, Week 26
Reported as:
Mean · mmol/L
Change in AUCIG,0-30min
mmol/LFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Baseline8.28 ± 2.757.80 ± 2.138.13 ± 1.87
Change from baseline-1.15 ± 3.620.22 ± 2.52-0.47 ± 2.81
SecondaryChange in AUCIG,0-1h

Change in area under the IG curve 0-1 hour post meal (AUCIG,0-1h) during meal test and based on CGM measurements was evaluated after 26 weeks of randomisation. IG was measured every 5 minutes. The endpoint was calculated as the area under the IG curve using the trapezoidal method and weighted by duration. A subgroup of participants wore a CGM for between 11 and 13 days up to week 0 (randomisation) and up to week 26 to monitor their IG on a continuous basis. The results are based on the last in-trial value.

Time frame:
Week 0, Week 26
Reported as:
Mean · mmol/L
Change in AUCIG,0-1h
mmol/LFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Baseline9.63 ± 2.909.43 ± 2.7110.02 ± 2.19
Change from baseline-0.87 ± 3.710.54 ± 3.00-0.65 ± 2.91
SecondaryChange in AUCIG,0-2h

Change in area under the IG curve 0-2 hours post meal (AUCIG,0-2h) during meal test and based on CGM measurements was evaluated after 26 weeks of randomisation. IG was measured every 5 minutes. The endpoint was calculated as the area under the IG curve using the trapezoidal method and weighted by duration. A subgroup of participants wore a CGM for between 11 and 13 days up to week 0 (randomisation) and up to week 26 to monitor their IG on a continuous basis. The results are based on the last in-trial value.

Time frame:
Week 0, Week 26
Reported as:
Mean · mmol/L
Change in AUCIG,0-2h
mmol/LFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Baseline11.40 ± 3.2011.48 ± 3.4311.76 ± 2.80
Change from baseline-0.84 ± 3.930.75 ± 3.74-0.86 ± 3.61
SecondaryChange in AUCIG,0-4h

Change in area under the IG curve 0-4 hours post meal (AUCIG,0-4h) during meal test and based on CGM measurements was evaluated after 26 weeks of randomisation. IG was measured every 5 minutes. The endpoint was calculated as the area under the IG curve using the trapezoidal method and weighted by duration. A subgroup of participants wore a CGM for between 11 and 13 days up to week 0 (randomisation) and up to week 26 to monitor their IG on a continuous basis. The results are based on the last in-trial value.

Time frame:
Week 0, Week 26
Reported as:
Mean · mmol/L
Change in AUCIG,0-4h
mmol/LFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Baseline11.21 ± 3.2511.19 ± 3.4711.46 ± 3.21
Change from baseline-0.38 ± 3.960.62 ± 3.97-1.30 ± 4.13
SecondaryChange in Time to the IG Peak After Start of Meal

Change in time to the IG peak after start of meal during meal test and based on CGM measurements was evaluated after 26 weeks of randomisation. A subgroup of participants wore a CGM for between 11 and 13 days up to week 0 (randomisation) and up to week 26 to monitor their IG on a continuous basis. Presented values are mean of all the meals (breakfast, lunch and evening meal). The results are based on the last in-trial value.

Time frame:
Week 0, Week 26
Reported as:
Mean · Minute
Change in Time to the IG Peak After Start of Meal
MinuteFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Baseline102.85 ± 48.9394.26 ± 38.2293.80 ± 39.19
Change from baseline5.29 ± 55.42-0.04 ± 42.05-8.76 ± 52.17
SecondaryChange in IG Peak After Start of Meal

Change in IG peak after start of meal during meal test and based on CGM measurements was evaluated after 26 weeks of randomisation. A subgroup of participants wore a CGM for between 11 and 13 days up to week 0 (randomisation) and up to week 26 to monitor their IG on a continuous basis. Presented values are mean of all the meals (breakfast, lunch and evening meal). The results are based on the last in-trial value.

Time frame:
Week 0, Week 26
Reported as:
Mean · mmol/L
Change in IG Peak After Start of Meal
mmol/LFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Baseline14.87 ± 3.5515.15 ± 4.5215.11 ± 3.62
Change from baseline-0.55 ± 3.771.11 ± 4.88-1.36 ± 4.36
SecondaryNumber of Treatment Emergent Hypoglycaemic Episodes According to American Diabetes Association (ADA)/ISPAD Classification: Total

Treatment emergent: if the onset of the episode occurred on or after the first day of treatment with investigational medicinal product (IMP) after randomisation, and no later than 1 day after the last day on IMP. Classification of hypoglycaemia: 1) Severe (according to ISPAD classification). Following are according to ADA classification: 2) Documented symptomatic: episode during which typical symptoms of hypoglycaemia are accompanied by a PG level ≤3.9 mmol/L. 3) Asymptomatic: episode not accompanied by typical symptoms of hypoglycaemia, but with a PG level ≤3.9 mmol/L. 4) Probable symptomatic: an episode during which symptoms of hypoglycaemia are not accompanied by a PG determination but that was presumably caused by a PG level ≤3.9 mmol/L. 5) Pseudo-hypoglycaemia: episode during which the person with diabetes reports any of the typical symptoms of hypoglycaemia with a PG level \>3.9mmol/L, but approaching that level. The results are based on the on-treatment period.

Time frame:
Week 0-26
Reported as:
Number · Episodes
Number of Treatment Emergent Hypoglycaemic Episodes According to American Diabetes Association (ADA)/ISPAD Classification: Total
EpisodesFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Severe384
Documented symptomatic539157125170
Asymptomatic425537813656
Probable symptomatic121024
Pseudo-hypoglycaemia353747
Unclassifiable521
SecondaryNumber of Treatment Emergent Hypoglycaemic Episodes According to ADA/ISPAD Classification: Daytime

Classification of hypoglycaemia: 1) Severe (according to ISPAD classification). Following are according to ADA classification: 2) Documented symptomatic. 3) Asymptomatic. 4) Probable symptomatic. 5) Pseudo-hypoglycaemia. Daytime period: The period between 07:01 and 22:59 (both included). The results are based on the on-treatment period.

Time frame:
Week 0-26
Reported as:
Number · Episodes
Number of Treatment Emergent Hypoglycaemic Episodes According to ADA/ISPAD Classification: Daytime
EpisodesFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Severe353
Documented symptomatic489550774779
Asymptomatic358431633101
Probable symptomatic101022
Pseudo-hypoglycaemia323142
Unclassifiable521
SecondaryNumber of Treatment Emergent Hypoglycaemic Episodes According to ADA/ISPAD Classification: Nocturnal (23:00-7:00, Both Included)

Classification of hypoglycaemia: 1) Severe (according to ISPAD classification). Following are according to ADA classification: 2) Documented symptomatic. 3) Asymptomatic. 4) Probable symptomatic. 5) Pseudo-hypoglycaemia. Nocturnal period: The period between 23:00 and 07:00 (both included). The results are based on the on-treatment period.

Time frame:
Week 0-26
Reported as:
Number · Episodes
Number of Treatment Emergent Hypoglycaemic Episodes According to ADA/ISPAD Classification: Nocturnal (23:00-7:00, Both Included)
EpisodesFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Severe031
Documented symptomatic496635391
Asymptomatic671618555
Probable symptomatic202
Pseudo-hypoglycaemia365
Unclassifiable000
SecondaryNumber of Treatment Emergent Hypoglycaemic Episodes According to Novo Nordisk/ISPAD Classification: Total

Classification of hypoglycaemia: 1) Severe (according to ISPAD classification). Following are according to Novo Nordisk classification: 2) Symptomatic blood glucose (BG) confirmed: episode that is BG confirmed by PG value \<3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. 3) Asymptomatic BG confirmed: episode that is BG confirmed by PG value \<3.1 mmol/L without symptoms consistent with hypoglycaemia. 4) Severe or BG confirmed symptomatic: an episode that is severe according to the ISPAD classification or BG confirmed by a PG value \<3.1 mmol/L with symptoms consistent with hypoglycaemia. 5) BG confirmed: an episode that is BG confirmed by a PG value \<3.1 mmol/L with or without symptoms consistent with hypoglycaemia. 6) Severe or BG confirmed: an episode that is severe according to the ISPAD Classification or BG confirmed by a PG value \<3.1 mmol/L with or without symptoms consistent with hypoglycaemia. The results are based on the on-treatment period.

Time frame:
Week 0-26
Reported as:
Number · Episodes
Number of Treatment Emergent Hypoglycaemic Episodes According to Novo Nordisk/ISPAD Classification: Total
EpisodesFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Severe384
BG confirmed358035863272
Severe or BG confirmed symptomatic224224272194
Severe or BG confirmed358335943276
Unclassifiable611859565626
SecondaryNumber of Treatment Emergent Hypoglycaemic Episodes According to Novo Nordisk/ISPAD Classification: Daytime

Classification of hypoglycaemia: 1) Severe (according to ISPAD classification). Following are according to Novo Nordisk classification: 2) BG confirmed. 3) Severe or BG confirmed symptomatic. 4) Severe or BG confirmed. 5) Asymptomatic BG confirmed. Daytime period: The period between 07:01 and 22:59 (both included). The results are based on the on-treatment period.

Time frame:
Week 0-26
Reported as:
Number · Episodes
Number of Treatment Emergent Hypoglycaemic Episodes According to Novo Nordisk/ISPAD Classification: Daytime
EpisodesFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Severe353
BG confirmed318431122960
Severe or BG confirmed symptomatic206221672035
Severe or BG confirmed318731172963
Unclassifiable534251714985
SecondaryNumber of Treatment Emergent Hypoglycaemic Episodes According to Novo Nordisk/ISPAD Classification: Nocturnal (23:00-7:00, Both Included)

Classification of hypoglycaemia: 1) Severe (according to ISPAD classification). Following are according to Novo Nordisk classification: 2) BG confirmed. 3) Severe or BG confirmed symptomatic. 4) Severe or BG confirmed. 5) Asymptomatic BG confirmed. Nocturnal period: The period between 23:00 and 07:00 (both included). The results are based on the on-treatment period.

Time frame:
Week 0-26
Reported as:
Number · Episodes
Number of Treatment Emergent Hypoglycaemic Episodes According to Novo Nordisk/ISPAD Classification: Nocturnal (23:00-7:00, Both Included)
EpisodesFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Severe031
BG confirmed396474312
Severe or BG confirmed symptomatic180260159
Severe or BG confirmed396477313
Unclassifiable776785641
SecondaryNumber of Treatment Emergent Meal Related (From Start of Meal Until 1 Hour After Start of Meal) Hypoglycaemic Episodes According to ADA/ISPAD Classification

Classification of hypoglycaemia: 1) Severe (according to ISPAD classification). Following are according to ADA classification: 2) Documented symptomatic. 3) Asymptomatic. 4) Probable symptomatic. 5) Pseudo-hypoglycaemia. The results are based on the on-treatment period.

Time frame:
Week 0-26
Reported as:
Number · Episodes
Number of Treatment Emergent Meal Related (From Start of Meal Until 1 Hour After Start of Meal) Hypoglycaemic Episodes According to ADA/ISPAD Classification
EpisodesFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Severe000
Documented symptomatic178113157
Asymptomatic775155
Probable symptomatic001
Pseudo-hypoglycaemia121
Unclassifiable000
SecondaryNumber of Treatment Emergent Meal Related (From Start of Meal Until 2 Hours After Start of Meal) Hypoglycaemic Episodes According to ADA/ISPAD Classification

Classification of hypoglycaemia: 1) Severe (according to ISPAD classification). Following are according to ADA classification: 2) Documented symptomatic. 3) Asymptomatic. 4) Probable symptomatic. 5) Pseudo-hypoglycaemia. The results are based on the on-treatment period.

Time frame:
Week 0-26
Reported as:
Number · Episodes
Number of Treatment Emergent Meal Related (From Start of Meal Until 2 Hours After Start of Meal) Hypoglycaemic Episodes According to ADA/ISPAD Classification
EpisodesFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Severe211
Documented symptomatic11258821016
Asymptomatic421268303
Probable symptomatic117
Pseudo-hypoglycaemia664
Unclassifiable000
SecondaryNumber of Treatment Emergent Meal Related (From Start of Meal Until 4 Hours After Start of Meal) Hypoglycaemic Episodes According to ADA/ISPAD Classification

Classification of hypoglycaemia: 1) Severe (according to ISPAD classification). Following are according to ADA classification: 2) Documented symptomatic. 3) Asymptomatic. 4) Probable symptomatic. 5) Pseudo-hypoglycaemia. The results are based on the on-treatment period.

Time frame:
Week 0-26
Reported as:
Number · Episodes
Number of Treatment Emergent Meal Related (From Start of Meal Until 4 Hours After Start of Meal) Hypoglycaemic Episodes According to ADA/ISPAD Classification
EpisodesFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Severe312
Documented symptomatic304130642812
Asymptomatic134011941168
Probable symptomatic4816
Pseudo-hypoglycaemia151817
Unclassifiable200
SecondaryNumber of Treatment Emergent Meal Related (From 2-4 Hours After Start of Meal) Hypoglycaemic Episodes According to ADA/ISPAD Classification

Classification of hypoglycaemia: 1) Severe (according to ISPAD classification). Following are according to ADA classification: 2) Documented symptomatic. 3) Asymptomatic. 4) Probable symptomatic. 5) Pseudo-hypoglycaemia. The results are based on the on-treatment period.

Time frame:
Week 0-26
Reported as:
Number · Episodes
Number of Treatment Emergent Meal Related (From 2-4 Hours After Start of Meal) Hypoglycaemic Episodes According to ADA/ISPAD Classification
EpisodesFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Severe101
Documented symptomatic191621821796
Asymptomatic919926865
Probable symptomatic379
Pseudo-hypoglycaemia91213
Unclassifiable200
SecondaryNumber of Treatment Emergent Meal Related (From Start of Meal Until 1 Hour After Start of Meal) Hypoglycaemic Episodes According to Novo Nordisk/ISPAD Classification

Classification of hypoglycaemia: 1) Severe (according to ISPAD classification). Following are according to Novo Nordisk classification: 2) BG confirmed. 3) Severe or BG confirmed symptomatic. 4) Severe or BG confirmed. 5) Asymptomatic BG confirmed. The results are based on the on-treatment period.

Time frame:
Week 0-26
Reported as:
Number · Episodes
Number of Treatment Emergent Meal Related (From Start of Meal Until 1 Hour After Start of Meal) Hypoglycaemic Episodes According to Novo Nordisk/ISPAD Classification
EpisodesFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Severe000
BG confirmed11966105
Severe or BG confirmed symptomatic944985
Severe or BG confirmed11966105
Unclassifiable137100109
SecondaryNumber of Treatment Emergent Meal Related (From Start of Meal Until 2 Hours After Start of Meal) Hypoglycaemic Episodes According to Novo Nordisk/ISPAD Classification

Classification of hypoglycaemia: 1) Severe (according to ISPAD classification). Following are according to Novo Nordisk classification: 2) BG confirmed. 3) Severe or BG confirmed symptomatic. 4) Severe or BG confirmed. 5) Asymptomatic BG confirmed. The results are based on the on-treatment period.

Time frame:
Week 0-26
Reported as:
Number · Episodes
Number of Treatment Emergent Meal Related (From Start of Meal Until 2 Hours After Start of Meal) Hypoglycaemic Episodes According to Novo Nordisk/ISPAD Classification
EpisodesFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Severe211
BG confirmed715504600
Severe or BG confirmed symptomatic572414495
Severe or BG confirmed717505601
Unclassifiable838653730
SecondaryNumber of Treatment Emergent Meal Related (From Start of Meal Until 4 Hours After Start of Meal) Hypoglycaemic Episodes According to Novo Nordisk/ISPAD Classification

Classification of hypoglycaemia: 1) Severe (according to ISPAD classification). Following are according to Novo Nordisk classification: 2) BG confirmed. 3) Severe or BG confirmed symptomatic. 4) Severe or BG confirmed. 5) Asymptomatic BG confirmed. The results are based on the on-treatment period.

Time frame:
Week 0-26
Reported as:
Number · Episodes
Number of Treatment Emergent Meal Related (From Start of Meal Until 4 Hours After Start of Meal) Hypoglycaemic Episodes According to Novo Nordisk/ISPAD Classification
EpisodesFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Severe312
BG confirmed177417811666
Severe or BG confirmed symptomatic136513751277
Severe or BG confirmed177717821668
Unclassifiable262825032347
SecondaryNumber of Treatment Emergent Meal Related (From 2-4 Hours After Start of Meal) Hypoglycaemic Episodes According to Novo Nordisk/ISPAD Classification

Classification of hypoglycaemia: 1) Severe (according to ISPAD classification). Following are according to Novo Nordisk classification: 2) BG confirmed. 3) Severe or BG confirmed symptomatic. 4) Severe or BG confirmed. 5) Asymptomatic BG confirmed. The results are based on the on-treatment period.

Time frame:
Week 0-26
Reported as:
Number · Episodes
Number of Treatment Emergent Meal Related (From 2-4 Hours After Start of Meal) Hypoglycaemic Episodes According to Novo Nordisk/ISPAD Classification
EpisodesFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Severe101
BG confirmed105912771066
Severe or BG confirmed symptomatic793961782
Severe or BG confirmed106012771067
Unclassifiable179018501617
SecondaryNumber of Treatment Emergent Adverse Events (AEs)

Treatment emergent was defined as an event that has onset up to 7 days after last day of IMP (faster aspart or NovoRapid®/NovoLog®) and excluding the events occurring in the run-in period. The results are based on the on-treatment period.

Time frame:
Week 0-26
Reported as:
Number · Events
Number of Treatment Emergent Adverse Events (AEs)
EventsFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Number of Treatment Emergent Adverse Events (AEs)576678593
SecondaryNumber of Treatment Emergent Injection Site Reactions

Treatment emergent was defined as an event that has onset up to 7 days after last day of IMP and excluding the events occurring in the run-in period. The results are based on the on-treatment period.

Time frame:
Week 0-26
Reported as:
Number · Events
Number of Treatment Emergent Injection Site Reactions
EventsFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Number of Treatment Emergent Injection Site Reactions113117
SecondaryChange in Physical Examination

The following physical examinations were done: 1) Cardiovascular system. 2) Central and peripheral nervous system. 3) Gastrointestinal system including the mouth. 4) General appearance. 5) Head, ears, eyes, nose, throat and neck. 6) Musculoskeletal system. 7) Respiratory system. 8) Skin. Presented results are number of participants with the following outcomes: normal, abnormal not clinically significant (NCS) and abnormal clinically significant (CS). Presented results are baseline (week 0) and last on-treatment values. Number of participants analysed = number of participants contributed to the analysis.

Time frame:
Week 0, Week 26
Reported as:
Number · Participants
Change in Physical Examination
ParticipantsFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
1) Baseline: Normal260254258
1) Baseline: Abnormal, NCS140
1) Baseline: Abnormal, CS000
1) Last on-treatment: Normal257253257
1) Last on-treatment: Abnormal, NCS050
1) Last on-treatment: Abnormal, CS000
2) Baseline: Normal257253258
2) Baseline: Abnormal, NCS340
2) Baseline: Abnormal, CS110
2) Last on-treatment: Normal255253257
2) Last on-treatment: Abnormal, NCS240
2) Last on-treatment: Abnormal, CS010
3) Baseline: Normal258257254
3) Baseline: Abnormal, NCS313
3) Baseline: Abnormal, CS001
3) Last on-treatment: Normal253257256
3) Last on-treatment: Abnormal, NCS410
3) Last on-treatment: Abnormal, CS001
4) Baseline: Normal258253254
4) Baseline: Abnormal, NCS234
4) Baseline: Abnormal, CS120
4) Last on-treatment: Normal257253254
4) Last on-treatment: Abnormal, NCS043
4) Last on-treatment: Abnormal, CS010
5) Baseline: Normal251238245
5) Baseline: Abnormal, NCS91311
5) Baseline: Abnormal, CS172
5) Last on-treatment: Normal247244242
5) Last on-treatment: Abnormal, NCS71114
5) Last on-treatment: Abnormal, CS331
6) Baseline: Normal259252254
6) Baseline: Abnormal, NCS243
6) Baseline: Abnormal, CS021
6) Last on-treatment: Normal254253253
6) Last on-treatment: Abnormal, NCS133
6) Last on-treatment: Abnormal, CS221
7) Baseline: Normal259256256
7) Baseline: Abnormal, NCS121
7) Baseline: Abnormal, CS101
7) Last on-treatment: Normal257258257
7) Last on-treatment: Abnormal, NCS000
7) Last on-treatment: Abnormal, CS000
8) Baseline: Normal239237238
8) Baseline: Abnormal, NCS182116
8) Baseline: Abnormal, CS404
8) Last on-treatment: Normal229233235
8) Last on-treatment: Abnormal, NCS192217
8) Last on-treatment: Abnormal, CS935
SecondaryChange in Vital Sign: Blood Pressure

Change from baseline (week 0) in blood pressure (systolic blood pressure (SBP) and diastolic blood pressure (DBP)) was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value.

Time frame:
Week 0, Week 26
Reported as:
Mean · mmHg
Change in Vital Sign: Blood Pressure
mmHgFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
SBP: Baseline106.4 ± 11.8107.0 ± 12.6106.8 ± 11.4
SBP: Change from baseline0.8 ± 11.01.5 ± 10.41.1 ± 10.1
DBP: Baseline65.4 ± 8.365.7 ± 9.465.4 ± 7.9
DBP: Change from baseline1.2 ± 9.11.4 ± 9.31.4 ± 8.3
SecondaryChange in Vital Sign: Pulse

Change from baseline (week 0) in pulse was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value.

Time frame:
Week 0, Week 26
Reported as:
Mean · Beats/minute
Change in Vital Sign: Pulse
Beats/minuteFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Baseline80.6 ± 11.880.5 ± 11.879.4 ± 11.8
Change from baseline-0.6 ± 10.30.3 ± 10.80.7 ± 11.0
SecondaryChange in Body Weight

Change from baseline (week 0) in body weight was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.

Time frame:
Week 0, Week 26
Reported as:
Mean · kg
Change in Body Weight
kgFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Baseline46.69 ± 18.1546.48 ± 18.9846.28 ± 17.18
Change from baseline2.21 ± 2.571.90 ± 2.322.15 ± 2.80
SecondaryChange in Height

Change from baseline (week 0) in height was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.

Time frame:
Week 0, Week 26
Reported as:
Mean · Meter
Change in Height
MeterFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Baseline1.50 ± 0.211.50 ± 0.211.50 ± 0.19
Change from baseline0.02 ± 0.020.02 ± 0.020.02 ± 0.02
SecondaryChange in Body Mass Index

Change from baseline (week 0) in body mass index (BMI) was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.

Time frame:
Week 0, Week 26
Reported as:
Mean · kg/m^2
Change in Body Mass Index
kg/m^2Faster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Baseline19.68 ± 3.7519.67 ± 4.0219.64 ± 3.78
Change from baseline0.37 ± 0.920.28 ± 0.920.34 ± 1.10
SecondaryChange in SD Score of Body Weight

Change from baseline (week 0) in standard deviation (SD) score of body weight was evaluated after 26 weeks of randomisation. SD-scores are defined to be able to normalise the body weight in the various age groups. To estimate the growth of children, standardised weight is calculated for each year of age and for each sex. Thus, a child with a weight equal to the mean value for its age and sex has an SD score of 0, while a child with a weight 2 SDs above the mean value for its age and sex has an SD score of +2. The SD scores are derived from the age and sex of the subjects and the body weight together with growth curves defined for a reference population. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.

Time frame:
Week 0, Week 26
Reported as:
Mean · Standard deviation score
Change in SD Score of Body Weight
Standard deviation scoreFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Baseline0.349 ± 0.9450.351 ± 0.9360.361 ± 0.875
Change from baseline0.034 ± 0.2310.008 ± 0.2230.030 ± 0.250
SecondaryChange in SD Score of Body Mass Index

Change from baseline (week 0) in SD score of BMI was evaluated after 26 weeks of randomisation. SD scores for BMI were determined in a similar way as SD scores for weight by use of a suitable reference population based on age and sex. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.

Time frame:
Week 0, Week 26
Reported as:
Mean · Standard deviation score
Change in SD Score of Body Mass Index
Standard deviation scoreFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Baseline0.296 ± 0.8950.298 ± 0.9360.317 ± 0.898
Change from baseline0.016 ± 0.3080.004 ± 0.3700.007 ± 0.338
SecondaryChange in Haematology: Haemoglobin

Change from baseline (week 0) in haemoglobin was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.

Time frame:
Week 0, Week 26
Reported as:
Mean · mmol/L
Change in Haematology: Haemoglobin
mmol/LFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Baseline8.33 ± 0.728.47 ± 0.748.41 ± 0.77
Change from baseline0.08 ± 0.510.09 ± 0.620.09 ± 0.52
SecondaryChange in Haematology: Haematocrit

Change from baseline (week 0) in haematocrit was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.

Time frame:
Week 0, Week 26
Reported as:
Mean · % of red blood cells
Change in Haematology: Haematocrit
% of red blood cellsFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Baseline40.87 ± 3.3941.51 ± 3.5041.34 ± 3.75
Change from baseline0.45 ± 2.860.40 ± 3.090.32 ± 2.75
SecondaryChange in Haematology: Erythrocytes

Change from baseline (week 0) in erythrocytes was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.

Time frame:
Week 0, Week 26
Reported as:
Mean · 10^12 cells/L
Change in Haematology: Erythrocytes
10^12 cells/LFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Baseline4.81 ± 0.394.87 ± 0.394.88 ± 0.40
Change from baseline0.02 ± 0.270.04 ± 0.310.02 ± 0.26
SecondaryChange in Haematology: Thrombocytes

Change from baseline (week 0) in thrombocytes was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.

Time frame:
Week 0, Week 26
Reported as:
Mean · 10^9 cells/L
Change in Haematology: Thrombocytes
10^9 cells/LFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Baseline268.1 ± 64.5270.0 ± 60.2262.5 ± 57.9
Change from baseline1.2 ± 47.31.6 ± 45.46.0 ± 44.9
SecondaryChange in Haematology: Leukocytes

Change from baseline (week 0) in leukocytes was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.

Time frame:
Week 0, Week 26
Reported as:
Mean · 10^9 cells/L
Change in Haematology: Leukocytes
10^9 cells/LFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Baseline6.10 ± 1.656.10 ± 1.636.11 ± 1.81
Change from baseline0.08 ± 1.660.14 ± 1.740.10 ± 1.67
SecondaryChange in Biochemistry: Creatinine

Change from baseline (week 0) in creatinine was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.

Time frame:
Week 0, Week 26
Reported as:
Mean · umol/L
Change in Biochemistry: Creatinine
umol/LFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Baseline51.8 ± 14.252.6 ± 13.352.1 ± 12.3
Change from baseline1.1 ± 7.81.5 ± 6.91.7 ± 6.8
SecondaryChange in Biochemistry: Alanine Aminotransferase (ALT)

Change from baseline (week 0) in ALT was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.

Time frame:
Week 0, Week 26
Reported as:
Mean · U/L
Change in Biochemistry: Alanine Aminotransferase (ALT)
U/LFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Baseline14.4 ± 6.414.7 ± 7.414.8 ± 5.6
Change from baseline0.1 ± 6.91.3 ± 14.90.5 ± 5.9
SecondaryChange in Biochemistry: Aspartate Aminotransferase (AST)

Change from baseline (week 0) in AST was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.

Time frame:
Week 0, Week 26
Reported as:
Mean · U/L
Change in Biochemistry: Aspartate Aminotransferase (AST)
U/LFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Baseline19.9 ± 6.820.0 ± 5.620.5 ± 5.9
Change from baseline0.1 ± 6.21.1 ± 11.7-0.4 ± 5.0
SecondaryChange in Biochemistry: Alkaline Phosphatase (AP)

Change from baseline (week 0) in AP was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.

Time frame:
Week 0, Week 26
Reported as:
Mean · U/L
Change in Biochemistry: Alkaline Phosphatase (AP)
U/LFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Baseline212.7 ± 135.8209.8 ± 94.9226.2 ± 93.6
Change from baseline-3.0 ± 119.0-1.7 ± 50.8-2.8 ± 80.4
SecondaryChange in Biochemistry: Sodium

Change from baseline (week 0) in sodium was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.

Time frame:
Week 0, Week 26
Reported as:
Mean · mmol/L
Change in Biochemistry: Sodium
mmol/LFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Baseline139.5 ± 2.5139.6 ± 2.4139.7 ± 2.5
Change from baseline0.5 ± 2.80.3 ± 2.70.04 ± 2.8
SecondaryChange in Biochemistry: Potassium

Change from baseline (week 0) in potassium was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.

Time frame:
Week 0, Week 26
Reported as:
Mean · mmol/L
Change in Biochemistry: Potassium
mmol/LFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Baseline4.48 ± 0.344.52 ± 0.344.52 ± 0.40
Change from baseline0.02 ± 0.41-0.06 ± 0.340.01 ± 0.50
SecondaryChange in Biochemistry: Albumin

Change from baseline (week 0) in albumin was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.

Time frame:
Week 0, Week 26
Reported as:
Mean · g/dL
Change in Biochemistry: Albumin
g/dLFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Baseline4.47 ± 0.244.51 ± 0.244.50 ± 0.25
Change from baseline0.01 ± 0.240.01 ± 0.250.005 ± 0.24
SecondaryChange in Biochemistry: Total Bilirubin

Change from baseline (week 0) in total bilirubin was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.

Time frame:
Week 0, Week 26
Reported as:
Mean · umol/L
Change in Biochemistry: Total Bilirubin
umol/LFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Baseline7.9 ± 6.07.9 ± 5.38.0 ± 6.2
Change from baseline0.2 ± 4.90.2 ± 3.40.3 ± 4.1
SecondaryChange in Lipid Profile: Total Cholesterol

Change from baseline (week 0) in total cholesterol after 26 weeks of randomisation is presented as ratio to baseline values. The results are based on the last on-treatment value.

Time frame:
Week 0, Week 26
Reported as:
Geometric mean · Ratio
Change in Lipid Profile: Total Cholesterol
RatioFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Change in Lipid Profile: Total Cholesterol0.989 ± 13.8691.023 ± 13.7421.016 ± 13.187
SecondaryChange in Lipid Profile: High Density Lipoproteins (HDL)

Change from baseline (week 0) in HDL after 26 weeks of randomisation is presented as ratio to baseline values. The results are based on the last on-treatment value.

Time frame:
Week 0, Week 26
Reported as:
Geometric mean · Ratio
Change in Lipid Profile: High Density Lipoproteins (HDL)
RatioFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Change in Lipid Profile: High Density Lipoproteins (HDL)1.004 ± 17.8651.030 ± 20.1801.023 ± 17.852
SecondaryChange in Lipid Profile: Low Density Lipoproteins (LDL)

Change from baseline (week 0) in LDL after 26 weeks of randomisation is presented as ratio to baseline values. The results are based on the last on-treatment value.

Time frame:
Week 0, Week 26
Reported as:
Geometric mean · Ratio
Change in Lipid Profile: Low Density Lipoproteins (LDL)
RatioFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Change in Lipid Profile: Low Density Lipoproteins (LDL)1.014 ± 19.5331.040 ± 19.6851.041 ± 19.864
SecondaryChange in Anti-insulin Aspart Antibody Development: Specific

Change from baseline (week 0) in 'antibodies specific for insulin aspart' was evaluated after 26 weeks of randomisation. This endpoint was measured as % bound radioactivity-labelled insulin aspart/Total added radioactivity-labelled insulin aspart (%B/T). The results are based on the last on-treatment value.

Time frame:
Week 0, Week 26
Reported as:
Mean · Percentage of B/T
Change in Anti-insulin Aspart Antibody Development: Specific
Percentage of B/TFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Baseline1.436 ± 3.1591.459 ± 5.3131.183 ± 2.134
Change from baseline-0.099 ± 1.015-0.213 ± 1.661-0.201 ± 1.238
SecondaryChange in Anti-insulin Aspart Antibody Development: Cross-reacting With Human Insulin

Change from baseline (week 0) in 'antibodies for insulin aspart, those cross-reacting with human insulin' was evaluated after 26 weeks of randomisation. This endpoint was measured as % bound radioactivity-labelled insulin aspart/Total added radioactivity-labelled insulin aspart (%B/T). The results are based on the last on-treatment value.

Time frame:
Week 0, Week 26
Reported as:
Mean · Percentage of B/T
Change in Anti-insulin Aspart Antibody Development: Cross-reacting With Human Insulin
Percentage of B/TFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Baseline18.794 ± 17.18921.576 ± 17.72120.156 ± 17.315
Change from baseline-3.202 ± 6.989-4.845 ± 7.034-3.802 ± 7.587
SecondaryChange in Anti-insulin Aspart Antibody Development: Total

Change from baseline (week 0) in 'total anti-insulin aspart antibodies (specific for insulin aspart and those cross-reacting with human insulin)' was evaluated after 26 weeks of randomisation. This endpoint was measured as % bound radioactivity-labelled insulin aspart/Total added radioactivity-labelled insulin aspart (%B/T). The results are based on the last on-treatment value.

Time frame:
Week 0, Week 26
Reported as:
Mean · Percentage of B/T
Change in Anti-insulin Aspart Antibody Development: Total
Percentage of B/TFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Baseline20.230 ± 17.79523.044 ± 18.07021.344 ± 17.825
Change from baseline-3.271 ± 7.158-5.061 ± 7.193-4.004 ± 7.700

Adverse events

Collected over Week 0 to week 26 + 7 days. Presented adverse events are treatment emergent.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Faster Aspart (Meal)0/261 (0%)5/261 (1.9%)137/261 (52.5%)
Faster Aspart (Post)0/258 (0%)13/258 (5%)149/258 (57.8%)
NovoRapid (Meal)0/258 (0%)9/258 (3.5%)136/258 (52.7%)
Most frequent serious events
Showing 10 of 22
Most frequent serious events
EventFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
GastroenteritisInfections and infestations0/2610/2583/258
Accidental overdoseInjury, poisoning and procedural complications1/2612/2580/258
Diabetic ketoacidosisMetabolism and nutrition disorders0/2612/2582/258
HypoglycaemiaMetabolism and nutrition disorders1/2612/2581/258
Hypoglycaemic unconsciousnessNervous system disorders0/2612/2580/258
AppendicitisInfections and infestations2/2610/2580/258
Abdominal painGastrointestinal disorders0/2610/2581/258
Adjustment disorder with mixed disturbance of emotion and conductPsychiatric disorders0/2611/2580/258
Diabetes mellitus inadequate controlMetabolism and nutrition disorders0/2610/2581/258
Diabetes mellitus managementSurgical and medical procedures0/2611/2580/258
Most frequent other events
Showing 10 of 11
Most frequent other events
EventFaster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)
Viral upper respiratory tract infectionInfections and infestations60/26153/25848/258
Upper respiratory tract infectionInfections and infestations22/26132/25826/258
HeadacheNervous system disorders16/26126/25822/258
PyrexiaGeneral disorders22/26116/25818/258
VomitingGastrointestinal disorders9/26121/2587/258
InfluenzaInfections and infestations20/26114/25814/258
GastroenteritisInfections and infestations13/26116/25819/258
CoughRespiratory, thoracic and mediastinal disorders10/26111/25816/258
RhinitisInfections and infestations10/26116/25811/258
Viral infectionInfections and infestations7/2619/25814/258

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Faster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)Total
Mean11.72 ± 3.7411.62 ± 3.6511.70 ± 3.4411.68 ± 3.61
Sex: Female, Male
Sex: Female, Male(Participants)Faster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)Total
Female126122110358
Male134137148419
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Faster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)Total
Hispanic or Latino16171245
Not Hispanic or Latino244242246732
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Faster Aspart (Meal)Faster Aspart (Post)NovoRapid (Meal)Total
American Indian or Alaska Native0112
Asian463743126
Native Hawaiian or Other Pacific Islander0000
Black or African American64515
White206217209632
More than one race0000
Unknown or Not Reported2002
09

Study locations

155 sites
  • Novo Nordisk Investigational Site
    Phoenix, Arizona 85053, United States
  • Novo Nordisk Investigational Site
    Tucson, Arizona 85724, United States
  • Novo Nordisk Investigational Site
    Long Beach, California 90806, United States
  • Novo Nordisk Investigational Site
    Los Angeles, California 90027, United States
  • Novo Nordisk Investigational Site
    Sacramento, California 95821, United States
  • Novo Nordisk Investigational Site
    Ventura, California 93003, United States
  • Novo Nordisk Investigational Site
    Aurora, Colorado 80045, United States
  • Novo Nordisk Investigational Site
    Gainesville, Florida 32608, United States
  • Novo Nordisk Investigational Site
    Jacksonville, Florida 32207, United States
  • Novo Nordisk Investigational Site
    Orlando, Florida 32806, United States
  • Novo Nordisk Investigational Site
    Tallahassee, Florida 32308, United States
  • Novo Nordisk Investigational Site
    Tampa, Florida 33612, United States
  • Novo Nordisk Investigational Site
    Atlanta, Georgia 30339, United States
  • Novo Nordisk Investigational Site
    Boise, Idaho 83712, United States
  • Novo Nordisk Investigational Site
    Idaho Falls, Idaho 83404-7596, United States
  • Novo Nordisk Investigational Site
    Springfield, Illinois 62702, United States
  • Novo Nordisk Investigational Site
    Lexington, Kentucky 40503, United States
  • Novo Nordisk Investigational Site
    Baltimore, Maryland 21229, United States
  • Novo Nordisk Investigational Site
    Boston, Massachusetts 02215, United States
  • Novo Nordisk Investigational Site
    Minneapolis, Minnesota 55416, United States
  • Novo Nordisk Investigational Site
    Minneapolis, Minnesota 55455, United States
  • Novo Nordisk Investigational Site
    Las Vegas, Nevada 89128, United States
  • Novo Nordisk Investigational Site
    Neptune, New Jersey 07753, United States
  • Novo Nordisk Investigational Site
    Buffalo, New York 14203, United States
  • Novo Nordisk Investigational Site
    Mineola, New York 11501, United States
  • Novo Nordisk Investigational Site
    Raleigh, North Carolina 27610, United States
  • Novo Nordisk Investigational Site
    Fargo, North Dakota 58122, United States
  • Novo Nordisk Investigational Site
    Columbus, Ohio 43205, United States
  • Novo Nordisk Investigational Site
    Tulsa, Oklahoma 74135, United States
  • Novo Nordisk Investigational Site
    Philadelphia, Pennsylvania 19104, United States
  • Novo Nordisk Investigational Site
    Philadelphia, Pennsylvania 19107, United States
  • Novo Nordisk Investigational Site
    Pittsburgh, Pennsylvania 15224, United States
  • Novo Nordisk Investigational Site
    Sioux Falls, South Dakota 57105, United States
  • Novo Nordisk Investigational Site
    Amarillo, Texas 79106, United States
  • Novo Nordisk Investigational Site
    Austin, Texas 78731, United States
  • Novo Nordisk Investigational Site
    Dallas, Texas 75231, United States
  • Novo Nordisk Investigational Site
    Dallas, Texas 75235, United States
  • Novo Nordisk Investigational Site
    Salt Lake City, Utah 84132, United States
  • Novo Nordisk Investigational Site
    Pleven, 5800, Bulgaria
  • Novo Nordisk Investigational Site
    Sofia, 1407, Bulgaria
  • Novo Nordisk Investigational Site
    Sofia, 1606, Bulgaria
  • Novo Nordisk Investigational Site
    Varna, 9010, Bulgaria
  • Novo Nordisk Investigational Site
    Hradec Kralove, 50005, Czechia
  • Novo Nordisk Investigational Site
    Opava, 746001, Czechia
  • Novo Nordisk Investigational Site
    Ostrava - Poruba, 70852, Czechia
  • Novo Nordisk Investigational Site
    Pardubice, 53203, Czechia
  • Novo Nordisk Investigational Site
    Praha, 10034, Czechia
  • Novo Nordisk Investigational Site
    Usti nad Labem, 40113, Czechia
  • Novo Nordisk Investigational Site
    Tallinn, 13419, Estonia
  • Novo Nordisk Investigational Site
    Tartu, 51014, Estonia
  • Novo Nordisk Investigational Site
    Espoo, 02740, Finland
  • Novo Nordisk Investigational Site
    OYS, 90029, Finland
  • Novo Nordisk Investigational Site
    Seinäjoki, 60220, Finland
  • Novo Nordisk Investigational Site
    Bochum, 44791, Germany
  • Novo Nordisk Investigational Site
    Freiburg, 79106, Germany
  • Novo Nordisk Investigational Site
    Hannover, 30173, Germany
  • Novo Nordisk Investigational Site
    Ludwigshafen, 67059, Germany
  • Novo Nordisk Investigational Site
    Münster, 48155, Germany
  • Novo Nordisk Investigational Site
    Neuwied, 56564, Germany
  • Novo Nordisk Investigational Site
    Oldenburg, 23758, Germany
  • Novo Nordisk Investigational Site
    Saint Ingbert-Oberwürzbach, 66386, Germany
  • Novo Nordisk Investigational Site
    Hyderabad, Andhra Pradesh 500003, India
  • Novo Nordisk Investigational Site
    Hyderabad, Andhra Pradesh 500072, India
  • Novo Nordisk Investigational Site
    Ahmedabad, Gujarat 380007, India
  • Novo Nordisk Investigational Site
    Kochi, Kerala 682041, India
  • Novo Nordisk Investigational Site
    Indore, Madhya Pradesh 452010, India
  • Novo Nordisk Investigational Site
    Mumbai, Maharashtra 400010, India
  • Novo Nordisk Investigational Site
    Pune, Maharashtra 411001, India
  • Novo Nordisk Investigational Site
    Chennai, Tamil Nadu 600 013, India
  • Novo Nordisk Investigational Site
    Kolkata, 700026, India
  • Novo Nordisk Investigational Site
    New Delhi, 110060, India
  • Novo Nordisk Investigational Site
    Beer Sheva, 84101, Israel
  • Novo Nordisk Investigational Site
    Haifa, 31096, Israel
  • Novo Nordisk Investigational Site
    Holon, 58100, Israel
  • Novo Nordisk Investigational Site
    Petah Tikva, 49202, Israel
  • Novo Nordisk Investigational Site
    Tel Aviv, Israel
  • Novo Nordisk Investigational Site
    Zerifin, 70300, Israel
  • Novo Nordisk Investigational Site
    Ancona, 60123, Italy
  • Novo Nordisk Investigational Site
    Catanzaro, 88100, Italy
  • Novo Nordisk Investigational Site
    Chieti, 66100, Italy
  • Novo Nordisk Investigational Site
    Napoli, 80131, Italy
  • Novo Nordisk Investigational Site
    Verona, 37126, Italy
  • Novo Nordisk Investigational Site
    Amagasaki-shi, Hyogo, 661-0965, Japan
  • Novo Nordisk Investigational Site
    Chuo-shi, Yamanashi, 409 3898, Japan
  • Novo Nordisk Investigational Site
    Fukuoka, 830-0011, Japan
  • Novo Nordisk Investigational Site
    Hiroshima-shi, Hiroshima, 734-8530, Japan
  • Novo Nordisk Investigational Site
    Iruma-gun, Saitama, 350 0495, Japan
  • Novo Nordisk Investigational Site
    Kitakyushu,Fukuoka, 8078556, Japan
  • Novo Nordisk Investigational Site
    Kitakyushu-shi, Fukuoka, 806-8501, Japan
  • Novo Nordisk Investigational Site
    Kobe-shi, Hyogo, 650-0047, Japan
  • Novo Nordisk Investigational Site
    Kobe-shi, Hyogo, 657-0846, Japan
  • Novo Nordisk Investigational Site
    Kochi-shi, Kochi, 780 0952, Japan
  • Novo Nordisk Investigational Site
    Kofu, Yamanashi, 400-0027, Japan
  • Novo Nordisk Investigational Site
    Kumamoto-shi, Kumamoto, 860 8556, Japan
  • Novo Nordisk Investigational Site
    Kure-shi, Hiroshima, 737-0023, Japan
  • Novo Nordisk Investigational Site
    Kyoto, 602-8566, Japan
  • Novo Nordisk Investigational Site
    Maebashi-shi, Gunma, 371-8511, Japan
  • Novo Nordisk Investigational Site
    Matsumoto-shi, Nagano,, 399-8701, Japan
  • Novo Nordisk Investigational Site
    Matsuyama-shi, Ehime, 790-8524, Japan
  • Novo Nordisk Investigational Site
    Musashino-shi, Tokyo, 180 0023, Japan

Showing the first 100 of 155 sites across 18 countries. Choose a country and city above to see the rest.

10

References and documents

Publications

  • Bode BW, Iotova V, Kovarenko M, Laffel LM, Rao PV, Deenadayalan S, Ekelund M, Larsen SF, Danne T. Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec, in Children and Adolescents With Type 1 Diabetes: The onset 7 Trial. Diabetes Care. 2019 Jul;42(7):1255-1262. doi: 10.2337/dc19-0009. Epub 2019 May 10. PubMed 31076415 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2016 to primary completion in Feb 2018, 21 months.

Results were first posted in Apr 2019, 1 year 1 month after primary completion.

Of 78 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 25. This study's 21 months is above that.

Counting every sponsor, half of 106 studies reached it within 18 months; a quarter within 10 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2016
First posted
Feb 2, 2016
StartActual
May 4, 2016
Primary completionActual
Feb 5, 2018
CompletionActual
Mar 3, 2018
Results first posted
Apr 4, 2019
Last update
Jun 5, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT02670915
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Feb 2, 2016
Start date
May 4, 2016
Primary completion
Feb 5, 2018
Completion
Mar 3, 2018
Results posted
Apr 4, 2019
Last update
Jun 5, 2019

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin Aspart

Start the discussion